

medicament for activating T cells and/or NK cells for the treatment of cancer, wherein said bispecific antibody monovalently binds a human PVRIG and monovalently binds TIGIT.

**[0015]** In some examples, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody that monovalently binds a human PVRIG and monovalently binds TIGIT for use in activating T cells and/or NK cells for the treatment of cancer.

**[0016]** In another aspect, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising: a) a first antigen binding portion comprising: i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody; wherein the anti-PVRIG antibody is selected from the group consisting of CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883), CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915), CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947), CHA.7.538\_1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979), CHA.7.538\_2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987), CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819), CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827), CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835), CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843), CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851), CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ ID NO:859), CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862, and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865, vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867), CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of

SEQ ID NO:870, and vhCDR3 of SEQ ID NO:871; and vlCDR1 of SEQ ID NO:873, vlCDR2 of SEQ ID NO:874, and vlCDR3 of SEQ ID NO:875), CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886, and vhCDR3 of SEQ ID NO:887; and vlCDR1 of SEQ ID NO:889, vlCDR2 of SEQ ID NO:890, and vlCDR3 of SEQ ID NO:891), CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894, and vhCDR3 of SEQ ID NO:895; and vlCDR1 of SEQ ID NO:897, vlCDR2 of SEQ ID NO:898, and vlCDR3 of SEQ ID NO:899), CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902, and vhCDR3 of SEQ ID NO:903; and vlCDR1 of SEQ ID NO:905, vlCDR2 of SEQ ID NO:906, and vlCDR3 of SEQ ID NO:907), CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918, and vhCDR3 of SEQ ID NO:919; and vlCDR1 of SEQ ID NO:921, vlCDR2 of SEQ ID NO:922, and vlCDR3 of SEQ ID NO:923), CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926, and vhCDR3 of SEQ ID NO:927; and vlCDR1 of SEQ ID NO:929, vlCDR2 of SEQ ID NO:930, and vlCDR3 of SEQ ID NO:931), CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934, and vhCDR3 of SEQ ID NO:935; and vlCDR1 of SEQ ID NO:937, vlCDR2 of SEQ ID NO:938, and vlCDR3 of SEQ ID NO:939), CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950, and vhCDR3 of SEQ ID NO:951; and vlCDR1 of SEQ ID NO:953, vlCDR2 of SEQ ID NO:954, and vlCDR3 of SEQ ID NO:955), CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958, and vhCDR3 of SEQ ID NO:959; and vlCDR1 of SEQ ID NO:961, vlCDR2 of SEQ ID NO:962, and vlCDR3 of SEQ ID NO:963), CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966, and vhCDR3 of SEQ ID NO:967; and vlCDR1 of SEQ ID NO:969, vlCDR2 of SEQ ID NO:970, and vlCDR3 of SEQ ID NO:971), CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990, and vhCDR3 of SEQ ID NO:991; and vlCDR1 of SEQ ID NO:993, vlCDR2 of SEQ ID NO:994, and vlCDR3 of SEQ ID NO:995), CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998, and vhCDR3 of SEQ ID NO:999; and vlCDR1 of SEQ ID NO:1001, vlCDR2 of SEQ ID NO:1002, and vlCDR3 of SEQ ID NO:1003), CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID NO:1006, and vhCDR3 of SEQ ID NO:1007; and vlCDR1 of SEQ ID NO:1009, vlCDR2 of SEQ ID NO:1010, and vlCDR3 of SEQ ID NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vlCDR1 of SEQ ID NO:1017, vlCDR2 of SEQ ID NO:1018, and vlCDR3 of SEQ ID NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vlCDR1 of SEQ ID NO:1025, vlCDR2 of SEQ ID NO:1026, and vlCDR3 of SEQ ID NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vlCDR1 of SEQ ID NO:1033, vlCDR2 of SEQ ID NO:1034, and vlCDR3 of SEQ ID NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vlCDR1 of SEQ ID NO:1041, vlCDR2 of SEQ ID NO:1042, and vlCDR3 of SEQ ID NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vlCDR1 of SEQ ID NO:1049, vlCDR2 of SEQ ID NO:1050, and vlCDR3 of SEQ ID NO:1051), CHA.7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of SEQ ID NO:1551, and vhCDR3 of SEQ ID NO:1552; and vlCDR1 of SEQ ID NO:1555, vlCDR2 of SEQ ID NO:1556, and

vlCDR3 of SEQ ID NO:1557), CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ ID NO:320, and vhCDR3 of SEQ ID NO:321; and vlCDR1 of SEQ ID NO:324, vlCDR2 of SEQ ID NO:325, and vlCDR3 of SEQ ID NO:326), CPA.7.001 (vhCDR1 of SEQ ID NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vlCDR1 of SEQ ID NO:174, vlCDR2 of SEQ ID NO:175, and vlCDR3 of SEQ ID NO:176), CPA.7.003 (vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID NO:181; and vlCDR1 of SEQ ID NO:184, vlCDR2 of SEQ ID NO:185, and vlCDR3 of SEQ ID NO:186), CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and vhCDR3 of SEQ ID NO:191; and vlCDR1 of SEQ ID NO:194, vlCDR2 of SEQ ID NO:195, and vlCDR3 of SEQ ID NO:196), CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vlCDR1 of SEQ ID NO:204, vlCDR2 of SEQ ID NO:205, and vlCDR3 of SEQ ID NO:206), CPA.7.008 (vhCDR1 of SEQ ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vlCDR1 of SEQ ID NO:214, vlCDR2 of SEQ ID NO:215, and vlCDR3 of SEQ ID NO:216), CPA.7.009 (vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID NO:221; and vlCDR1 of SEQ ID NO:224, vlCDR2 of SEQ ID NO:225, and vlCDR3 of SEQ ID NO:226), CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and vhCDR3 of SEQ ID NO:231; and vlCDR1 of SEQ ID NO:234, vlCDR2 of SEQ ID NO:235, and vlCDR3 of SEQ ID NO:236), CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vlCDR1 of SEQ ID NO:244, vlCDR2 of SEQ ID NO:245, and vlCDR3 of SEQ ID NO:246), CPA.7.012 (vhCDR1 of SEQ ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vlCDR1 of SEQ ID NO:254, vlCDR2 of SEQ ID NO:255, and vlCDR3 of SEQ ID NO:256), CPA.7.013 (vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID NO:261; and vlCDR1 of SEQ ID NO:264, vlCDR2 of SEQ ID NO:265, and vlCDR3 of SEQ ID NO:266), CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270, and vhCDR3 of SEQ ID NO:271; and vlCDR1 of SEQ ID NO:274, vlCDR2 of SEQ ID NO:275, and vlCDR3 of SEQ ID NO:276), CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of SEQ ID NO:280, and vhCDR3 of SEQ ID NO:281; and vlCDR1 of SEQ ID NO:284, vlCDR2 of SEQ ID NO:285, and vlCDR3 of SEQ ID NO:286), CPA.7.017 (vhCDR1 of SEQ ID NO:289, vhCDR2 of SEQ ID NO:290, and vhCDR3 of SEQ ID NO:291; and vlCDR1 of SEQ ID NO:294, vlCDR2 of SEQ ID NO:295, and vlCDR3 of SEQ ID NO:296), CPA.7.018 (vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300, and vhCDR3 of SEQ ID NO:301; and vlCDR1 of SEQ ID NO:304, vlCDR2 of SEQ ID NO:305, and vlCDR3 of SEQ ID NO:306), CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310, and vhCDR3 of SEQ ID NO:311; and vlCDR1 of SEQ ID NO:314, vlCDR2 of SEQ ID NO:315, and vlCDR3 of SEQ ID NO:316), CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of SEQ ID NO:330, and vhCDR3 of SEQ ID NO:331; and vlCDR1 of SEQ ID NO:334, vlCDR2 of SEQ ID NO:335, and vlCDR3 of SEQ ID NO:336), CPA.7.023 (vhCDR1 of SEQ ID NO:339, vhCDR2 of SEQ ID NO:340, and vhCDR3 of SEQ ID NO:341; and vlCDR1 of SEQ ID NO:344, vlCDR2 of SEQ ID NO:345, and vlCDR3 of SEQ ID NO:346), CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350, and vhCDR3 of SEQ ID NO:351; and vlCDR1 of SEQ ID NO:354, vlCDR2 of SEQ ID NO:355, and vlCDR3 of SEQ

ID NO:356), CPA.7.033 (vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360, and vhCDR3 of SEQ ID NO:361; and vlCDR1 of SEQ ID NO:364, vlCDR2 of SEQ ID NO:365, and vlCDR3 of SEQ ID NO:366), CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370, and vhCDR3 of SEQ ID NO:371; and vlCDR1 of SEQ ID NO:374, vlCDR2 of SEQ ID NO:375, and vlCDR3 of SEQ ID NO:376), CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380, and vhCDR3 of SEQ ID NO:381; and vlCDR1 of SEQ ID NO:384, vlCDR2 of SEQ ID NO:385, and vlCDR3 of SEQ ID NO:386), CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390, and vhCDR3 of SEQ ID NO:391; and vlCDR1 of SEQ ID NO:394, vlCDR2 of SEQ ID NO:395, and vlCDR3 of SEQ ID NO:396), CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400, and vhCDR3 of SEQ ID NO:401; and vlCDR1 of SEQ ID NO:404, vlCDR2 of SEQ ID NO:405, and vlCDR3 of SEQ ID NO:406), CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410, and vhCDR3 of SEQ ID NO:411; and vlCDR1 of SEQ ID NO:414, vlCDR2 of SEQ ID NO:415, and vlCDR3 of SEQ ID NO:416), CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420, and vhCDR3 of SEQ ID NO:421; and vlCDR1 of SEQ ID NO:424, vlCDR2 of SEQ ID NO:425, and vlCDR3 of SEQ ID NO:426), and CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430, and vhCDR3 of SEQ ID NO:431; and vlCDR1 of SEQ ID NO:434, vlCDR2 of SEQ ID NO:435, and vlCDR3 of SEQ ID NO:436) and b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.

**[0016a]** In some aspects/examples, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising:
  - i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
  - ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody;

wherein the anti-PVRIG antibody is selected from the group consisting of CHA.7.518.4, CHA.7.518.1, CHA.7.518, CHA.7.524 CHA.7.530, CHA.7.538\_1, CHA.7.538\_2, CHA.7.502, CHA.7.503, CHA.7.506, CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514, CHA.7.516, CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522, CHA.7.524, CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530, CHA.7.534, CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2, CHA.7.543, CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547, CHA.7.548, CHA.7.549, CHA.7.550, CHA.7.538.1.2, CPA.7.021, CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009, CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015, CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024, CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047, CPA.7.049, CPA.7.050, and CHA.7.518; and

- a) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.

**[0017]** In another aspect, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising: a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and b) a second antigen binding portion comprising: a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody; wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vlCDR1 of SEQ ID NO:1640, vlCDR2 of SEQ ID NO:1641, and vlCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vlCDR1 of SEQ ID NO:1669, vlCDR2 of SEQ ID NO:1670, and vlCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vlCDR1 of SEQ ID NO:1678, vlCDR2 of SEQ ID NO:1679, and vlCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vlCDR1 of SEQ ID NO:1688, vlCDR2 of SEQ ID NO:1689, and vlCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vlCDR1 of SEQ ID NO:1698, vlCDR2 of SEQ ID NO:1699, and vlCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vlCDR1 of SEQ ID NO:1708, vlCDR2 of SEQ ID NO:1709, and vlCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vlCDR1 of SEQ ID NO:1718, vlCDR2 of SEQ ID NO:1719, and vlCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vlCDR1 of SEQ ID NO:1728, vlCDR2 of SEQ ID NO:1729, and vlCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vlCDR1 of SEQ ID NO:1748, vlCDR2 of SEQ ID NO:1749, and vlCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vlCDR1 of SEQ ID NO:1758, vlCDR2 of SEQ ID NO:1759, and vlCDR3 of SEQ ID NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vlCDR1 of SEQ ID NO:1768, vlCDR2 of SEQ ID NO:1769, and vlCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vlCDR1 of SEQ ID NO:1778, vlCDR2 of SEQ ID NO:1779, and vlCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vlCDR1 of SEQ ID NO:1808, vlCDR2 of SEQ ID NO:1809, and vlCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vlCDR1 of SEQ ID NO:1818, vlCDR2 of SEQ ID NO:1819, and vlCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and

vhCDR3 of SEQ ID NO:1825; and vlCDR1 of SEQ ID NO:1828, vlCDR2 of SEQ ID NO:1829, and vlCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vlCDR1 of SEQ ID NO:1838, vlCDR2 of SEQ ID NO:1839, and vlCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vlCDR1 of SEQ ID NO:1848, vlCDR2 of SEQ ID NO:1849, and vlCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vlCDR1 of SEQ ID NO:1858, vlCDR2 of SEQ ID NO:1859, and vlCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vlCDR1 of SEQ ID NO:1868, vlCDR2 of SEQ ID NO:1869, and vlCDR3 of SEQ ID NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vlCDR1 of SEQ ID NO:1878, vlCDR2 of SEQ ID NO:1879, and vlCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vlCDR1 of SEQ ID NO:1888, vlCDR2 of SEQ ID NO:1889, and vlCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vlCDR1 of SEQ ID NO:1898, vlCDR2 of SEQ ID NO:1899, and vlCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vlCDR1 of SEQ ID NO:1908, vlCDR2 of SEQ ID NO:1909, and vlCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vlCDR1 of SEQ ID NO:1918, vlCDR2 of SEQ ID NO:1919, and vlCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vlCDR1 of SEQ ID NO:1928, vlCDR2 of SEQ ID NO:1929, and vlCDR3 of SEQ ID NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vlCDR1 of SEQ ID NO:1938, vlCDR2 of SEQ ID NO:1939, and vlCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vlCDR1 of SEQ ID NO:1948, vlCDR2 of SEQ ID NO:1949, and vlCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vlCDR1 of SEQ ID NO:1958, vlCDR2 of SEQ ID NO:1959, and vlCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vlCDR1 of SEQ ID NO:1968, vlCDR2 of SEQ ID NO:1969, and vlCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vlCDR1 of SEQ ID NO:1978, vlCDR2 of SEQ ID NO:1979, and vlCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and vhCDR3 of SEQ ID NO:1985; and vlCDR1 of SEQ ID NO:1988, vlCDR2 of SEQ ID NO:1989, and vlCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vlCDR1 of SEQ ID NO:1998, vlCDR2 of SEQ ID NO:1999, and vlCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID

NO:2005; and vLCDR1 of SEQ ID NO:2008, vLCDR2 of SEQ ID NO:2009, and vLCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vLCDR1 of SEQ ID NO:2018, vLCDR2 of SEQ ID NO:2019, and vLCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vLCDR1 of SEQ ID NO:2028, vLCDR2 of SEQ ID NO:2029, and vLCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vLCDR1 of SEQ ID NO:1660, vLCDR2 of SEQ ID NO:1661, and vLCDR3 of SEQ ID NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vLCDR1 of SEQ ID NO:2038, vLCDR2 of SEQ ID NO:2039, and vLCDR3 of SEQ ID NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vLCDR1 of SEQ ID NO:2048, vLCDR2 of SEQ ID NO:2049, and vLCDR3 of SEQ ID NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vLCDR1 of SEQ ID NO:2058, vLCDR2 of SEQ ID NO:2059, and vLCDR3 of SEQ ID NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vLCDR1 of SEQ ID NO:2068, vLCDR2 of SEQ ID NO:2069, and vLCDR3 of SEQ ID NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vLCDR1 of SEQ ID NO:2078, vLCDR2 of SEQ ID NO:2079, and vLCDR3 of SEQ ID NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vLCDR1 of SEQ ID NO:2088, vLCDR2 of SEQ ID NO:2089, and vLCDR3 of SEQ ID NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vLCDR1 of SEQ ID NO:2098, vLCDR2 of SEQ ID NO:2099, and vLCDR3 of SEQ ID NO:2100).

**[0017a]** In some aspectsexamples, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and
- b) a second antigen binding portion comprising:
  - i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
  - ii. a second light chain variable domain comprising a vLCDR1, vLCDR2, and vLCDR3 from an anti-TIGIT antibody;
 wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086, CHA.9.547.18, CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059, CPA.9.083, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103, CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6, CHA.9.536.7, CHA.9.536.8,

CHA.9.560.1, CHA.9.560.3, CHA.9.560.4, CHA.9.560.5,  
CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1,  
CHA.9.547.1, CHA.9.547.2, CHA.9.547.3, CHA.9.547.4,  
CHA.9.547.6, CHA.9.547.7, CHA.9.547.8, CHA.9.547.9,  
CHA.9.547.13, CHA.9.541.1, CHA.9.541.3, CHA.9.541.4,  
CHA.9.541.5, CHA.9.541.6, CHA.9.541.7, and CHA.9.541.8.

**[0018]** In yet another aspect, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising: a) a first antigen binding portion comprising: i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody wherein the anti-PVRIG antibody is selected from the group consisting of CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883), CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915), CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947), CHA.7.538\_1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979), CHA.7.538\_2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987), CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819), CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827), CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835), CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843), CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851), CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ

ID NO:859), CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862, and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865, vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867), CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of SEQ ID NO:870, and vhCDR3 of SEQ ID NO:871; and vlCDR1 of SEQ ID NO:873, vlCDR2 of SEQ ID NO:874, and vlCDR3 of SEQ ID NO:875), CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886, and vhCDR3 of SEQ ID NO:887; and vlCDR1 of SEQ ID NO:889, vlCDR2 of SEQ ID NO:890, and vlCDR3 of SEQ ID NO:891), CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894, and vhCDR3 of SEQ ID NO:895; and vlCDR1 of SEQ ID NO:897, vlCDR2 of SEQ ID NO:898, and vlCDR3 of SEQ ID NO:899), CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902, and vhCDR3 of SEQ ID NO:903; and vlCDR1 of SEQ ID NO:905, vlCDR2 of SEQ ID NO:906, and vlCDR3 of SEQ ID NO:907), CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918, and vhCDR3 of SEQ ID NO:919; and vlCDR1 of SEQ ID NO:921, vlCDR2 of SEQ ID NO:922, and vlCDR3 of SEQ ID NO:923), CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926, and vhCDR3 of SEQ ID NO:927; and vlCDR1 of SEQ ID NO:929, vlCDR2 of SEQ ID NO:930, and vlCDR3 of SEQ ID NO:931), CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934, and vhCDR3 of SEQ ID NO:935; and vlCDR1 of SEQ ID NO:937, vlCDR2 of SEQ ID NO:938, and vlCDR3 of SEQ ID NO:939), CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950, and vhCDR3 of SEQ ID NO:951; and vlCDR1 of SEQ ID NO:953, vlCDR2 of SEQ ID NO:954, and vlCDR3 of SEQ ID NO:955), CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958, and vhCDR3 of SEQ ID NO:959; and vlCDR1 of SEQ ID NO:961, vlCDR2 of SEQ ID NO:962, and vlCDR3 of SEQ ID NO:963), CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966, and vhCDR3 of SEQ ID NO:967; and vlCDR1 of SEQ ID NO:969, vlCDR2 of SEQ ID NO:970, and vlCDR3 of SEQ ID NO:971), CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990, and vhCDR3 of SEQ ID NO:991; and vlCDR1 of SEQ ID NO:993, vlCDR2 of SEQ ID NO:994, and vlCDR3 of SEQ ID NO:995), CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998, and vhCDR3 of SEQ ID NO:999; and vlCDR1 of SEQ ID NO:1001, vlCDR2 of SEQ ID NO:1002, and vlCDR3 of SEQ ID NO:1003), CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID NO:1006, and vhCDR3 of SEQ ID NO:1007; and vlCDR1 of SEQ ID NO:1009, vlCDR2 of SEQ ID NO:1010, and vlCDR3 of SEQ ID NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vlCDR1 of SEQ ID NO:1017, vlCDR2 of SEQ ID NO:1018, and vlCDR3 of SEQ ID NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vlCDR1 of SEQ ID NO:1025, vlCDR2 of SEQ ID NO:1026, and vlCDR3 of SEQ ID NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vlCDR1 of SEQ ID NO:1033, vlCDR2 of SEQ ID NO:1034, and vlCDR3 of SEQ ID NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vlCDR1 of SEQ ID NO:1041, vlCDR2 of SEQ ID NO:1042, and vlCDR3 of SEQ ID NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vlCDR1 of

SEQ ID NO:1049, vLCDR2 of SEQ ID NO:1050, and vLCDR3 of SEQ ID NO:1051),  
CHA7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of SEQ ID NO:1551, and vhCDR3  
of SEQ ID NO:1552; and vLCDR1 of SEQ ID NO:1555, vLCDR2 of SEQ ID NO:1556, and  
vLCDR3 of SEQ ID NO:1557), CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ  
ID NO:320, and vhCDR3 of SEQ ID NO:321; and vLCDR1 of SEQ ID NO:324, vLCDR2 of  
SEQ ID NO:325, and vLCDR3 of SEQ ID NO:326), CPA.7.001 (vhCDR1 of SEQ ID  
NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vLCDR1 of  
SEQ ID NO:174, vLCDR2 of SEQ ID NO:175, and vLCDR3 of SEQ ID NO:176), CPA.7.003  
(vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID  
NO:181; and vLCDR1 of SEQ ID NO:184, vLCDR2 of SEQ ID NO:185, and vLCDR3 of SEQ  
ID NO:186), CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and  
vhCDR3 of SEQ ID NO:191; and vLCDR1 of SEQ ID NO:194, vLCDR2 of SEQ ID NO:195,  
and vLCDR3 of SEQ ID NO:196), CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of  
SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vLCDR1 of SEQ ID NO:204,  
vLCDR2 of SEQ ID NO:205, and vLCDR3 of SEQ ID NO:206), CPA.7.008 (vhCDR1 of SEQ  
ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vLCDR1 of  
SEQ ID NO:214, vLCDR2 of SEQ ID NO:215, and vLCDR3 of SEQ ID NO:216), CPA.7.009  
(vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID  
NO:221; and vLCDR1 of SEQ ID NO:224, vLCDR2 of SEQ ID NO:225, and vLCDR3 of SEQ  
ID NO:226), CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and  
vhCDR3 of SEQ ID NO:231; and vLCDR1 of SEQ ID NO:234, vLCDR2 of SEQ ID NO:235,  
and vLCDR3 of SEQ ID NO:236), CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of  
SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vLCDR1 of SEQ ID NO:244,  
vLCDR2 of SEQ ID NO:245, and vLCDR3 of SEQ ID NO:246), CPA.7.012 (vhCDR1 of SEQ  
ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vLCDR1 of  
SEQ ID NO:254, vLCDR2 of SEQ ID NO:255, and vLCDR3 of SEQ ID NO:256), CPA.7.013  
(vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID  
NO:261; and vLCDR1 of SEQ ID NO:264, vLCDR2 of SEQ ID NO:265, and vLCDR3 of SEQ  
ID NO:266), CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270, and  
vhCDR3 of SEQ ID NO:271; and vLCDR1 of SEQ ID NO:274, vLCDR2 of SEQ ID NO:275,  
and vLCDR3 of SEQ ID NO:276), CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of  
SEQ ID NO:280, and vhCDR3 of SEQ ID NO:281; and vLCDR1 of SEQ ID NO:284,  
vLCDR2 of SEQ ID NO:285, and vLCDR3 of SEQ ID NO:286), CPA.7.017 (vhCDR1 of SEQ  
ID NO:289, vhCDR2 of SEQ ID NO:290, and vhCDR3 of SEQ ID NO:291; and vLCDR1 of  
SEQ ID NO:294, vLCDR2 of SEQ ID NO:295, and vLCDR3 of SEQ ID NO:296), CPA.7.018  
(vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300, and vhCDR3 of SEQ ID  
NO:301; and vLCDR1 of SEQ ID NO:304, vLCDR2 of SEQ ID NO:305, and vLCDR3 of SEQ  
ID NO:306), CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310, and  
vhCDR3 of SEQ ID NO:311; and vLCDR1 of SEQ ID NO:314, vLCDR2 of SEQ ID NO:315,  
and vLCDR3 of SEQ ID NO:316), CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of  
SEQ ID NO:330, and vhCDR3 of SEQ ID NO:331; and vLCDR1 of SEQ ID NO:334,  
vLCDR2 of SEQ ID NO:335, and vLCDR3 of SEQ ID NO:336), CPA.7.023 (vhCDR1 of SEQ  
ID NO:339, vhCDR2 of SEQ ID NO:340, and vhCDR3 of SEQ ID NO:341; and vLCDR1 of

SEQ ID NO:344, vLCDR2 of SEQ ID NO:345, and vLCDR3 of SEQ ID NO:346), CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350, and vhCDR3 of SEQ ID NO:351; and vLCDR1 of SEQ ID NO:354, vLCDR2 of SEQ ID NO:355, and vLCDR3 of SEQ ID NO:356), CPA.7.033 (vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360, and vhCDR3 of SEQ ID NO:361; and vLCDR1 of SEQ ID NO:364, vLCDR2 of SEQ ID NO:365, and vLCDR3 of SEQ ID NO:366), CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370, and vhCDR3 of SEQ ID NO:371; and vLCDR1 of SEQ ID NO:374, vLCDR2 of SEQ ID NO:375, and vLCDR3 of SEQ ID NO:376), CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380, and vhCDR3 of SEQ ID NO:381; and vLCDR1 of SEQ ID NO:384, vLCDR2 of SEQ ID NO:385, and vLCDR3 of SEQ ID NO:386), CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390, and vhCDR3 of SEQ ID NO:391; and vLCDR1 of SEQ ID NO:394, vLCDR2 of SEQ ID NO:395, and vLCDR3 of SEQ ID NO:396), CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400, and vhCDR3 of SEQ ID NO:401; and vLCDR1 of SEQ ID NO:404, vLCDR2 of SEQ ID NO:405, and vLCDR3 of SEQ ID NO:406), CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410, and vhCDR3 of SEQ ID NO:411; and vLCDR1 of SEQ ID NO:414, vLCDR2 of SEQ ID NO:415, and vLCDR3 of SEQ ID NO:416), CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420, and vhCDR3 of SEQ ID NO:421; and vLCDR1 of SEQ ID NO:424, vLCDR2 of SEQ ID NO:425, and vLCDR3 of SEQ ID NO:426), and CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430, and vhCDR3 of SEQ ID NO:431; and vLCDR1 of SEQ ID NO:434, vLCDR2 of SEQ ID NO:435, and vLCDR3 of SEQ ID NO:436); and b) a second antigen binding portion comprising: i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and ii. a second light chain variable domain comprising a vLCDR1, vLCDR2, and vLCDR3 from an anti-TIGIT antibody; wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vLCDR1 of SEQ ID NO:1640, vLCDR2 of SEQ ID NO:1641, and vLCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vLCDR1 of SEQ ID NO:1669, vLCDR2 of SEQ ID NO:1670, and vLCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vLCDR1 of SEQ ID NO:1678, vLCDR2 of SEQ ID NO:1679, and vLCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vLCDR1 of SEQ ID NO:1688, vLCDR2 of SEQ ID NO:1689, and vLCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vLCDR1 of SEQ ID NO:1698, vLCDR2 of SEQ ID NO:1699, and vLCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vLCDR1 of SEQ ID NO:1708, vLCDR2 of SEQ ID NO:1709, and vLCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vLCDR1 of SEQ ID NO:1718, vLCDR2 of SEQ ID NO:1719, and vLCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vLCDR1 of

SEQ ID NO:1728, vLCDR2 of SEQ ID NO:1729, and vLCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vLCDR1 of SEQ ID NO:1748, vLCDR2 of SEQ ID NO:1749, and vLCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vLCDR1 of SEQ ID NO:1758, vLCDR2 of SEQ ID NO:1759, and vLCDR3 of SEQ ID NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vLCDR1 of SEQ ID NO:1768, vLCDR2 of SEQ ID NO:1769, and vLCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vLCDR1 of SEQ ID NO:1778, vLCDR2 of SEQ ID NO:1779, and vLCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vLCDR1 of SEQ ID NO:1808, vLCDR2 of SEQ ID NO:1809, and vLCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vLCDR1 of SEQ ID NO:1818, vLCDR2 of SEQ ID NO:1819, and vLCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and vhCDR3 of SEQ ID NO:1825; and vLCDR1 of SEQ ID NO:1828, vLCDR2 of SEQ ID NO:1829, and vLCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vLCDR1 of SEQ ID NO:1838, vLCDR2 of SEQ ID NO:1839, and vLCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vLCDR1 of SEQ ID NO:1848, vLCDR2 of SEQ ID NO:1849, and vLCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vLCDR1 of SEQ ID NO:1858, vLCDR2 of SEQ ID NO:1859, and vLCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vLCDR1 of SEQ ID NO:1868, vLCDR2 of SEQ ID NO:1869, and vLCDR3 of SEQ ID NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vLCDR1 of SEQ ID NO:1878, vLCDR2 of SEQ ID NO:1879, and vLCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vLCDR1 of SEQ ID NO:1888, vLCDR2 of SEQ ID NO:1889, and vLCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vLCDR1 of SEQ ID NO:1898, vLCDR2 of SEQ ID NO:1899, and vLCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vLCDR1 of SEQ ID NO:1908, vLCDR2 of SEQ ID NO:1909, and vLCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vLCDR1 of SEQ ID NO:1918, vLCDR2 of SEQ ID NO:1919, and vLCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vLCDR1 of SEQ ID NO:1928, vLCDR2 of SEQ ID NO:1929, and vLCDR3 of SEQ ID NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vLCDR1 of SEQ ID NO:1938, vLCDR2 of

SEQ ID NO:1939, and vLCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vLCDR1 of SEQ ID NO:1948, vLCDR2 of SEQ ID NO:1949, and vLCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vLCDR1 of SEQ ID NO:1958, vLCDR2 of SEQ ID NO:1959, and vLCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vLCDR1 of SEQ ID NO:1968, vLCDR2 of SEQ ID NO:1969, and vLCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vLCDR1 of SEQ ID NO:1978, vLCDR2 of SEQ ID NO:1979, and vLCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and vhCDR3 of SEQ ID NO:1985; and vLCDR1 of SEQ ID NO:1988, vLCDR2 of SEQ ID NO:1989, and vLCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vLCDR1 of SEQ ID NO:1998, vLCDR2 of SEQ ID NO:1999, and vLCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID NO:2005; and vLCDR1 of SEQ ID NO:2008, vLCDR2 of SEQ ID NO:2009, and vLCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vLCDR1 of SEQ ID NO:2018, vLCDR2 of SEQ ID NO:2019, and vLCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vLCDR1 of SEQ ID NO:2028, vLCDR2 of SEQ ID NO:2029, and vLCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vLCDR1 of SEQ ID NO:1660, vLCDR2 of SEQ ID NO:1661, and vLCDR3 of SEQ ID NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vLCDR1 of SEQ ID NO:2038, vLCDR2 of SEQ ID NO:2039, and vLCDR3 of SEQ ID NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vLCDR1 of SEQ ID NO:2048, vLCDR2 of SEQ ID NO:2049, and vLCDR3 of SEQ ID NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vLCDR1 of SEQ ID NO:2058, vLCDR2 of SEQ ID NO:2059, and vLCDR3 of SEQ ID NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vLCDR1 of SEQ ID NO:2068, vLCDR2 of SEQ ID NO:2069, and vLCDR3 of SEQ ID NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vLCDR1 of SEQ ID NO:2078, vLCDR2 of SEQ ID NO:2079, and vLCDR3 of SEQ ID NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vLCDR1 of SEQ ID NO:2088, vLCDR2 of SEQ ID NO:2089, and vLCDR3 of SEQ ID NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vLCDR1 of SEQ ID NO:2098, vLCDR2 of SEQ ID NO:2099, and vLCDR3 of SEQ ID NO:2100).

**[0018a]** In some examplesaspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising:
- i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
  - ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody
- wherein the anti-PVRIG antibody is selected from the group consisting of CHA.7.518.4, CHA.7.518.1, humanized CHA.7.518, humanized CHA.7.524, humanized CHA.7.530, humanized CHA.7.538\_1, humanized CHA.7.538\_2, CHA.7.502, CHA.7.503, CHA.7.506, CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514, CHA.7.516, CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522, CHA.7.524, CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530, CHA.7.534, CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2, CHA.7.543, CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547, CHA.7.548, CHA.7.549, CHA.7.550, CHA.7.538.1.2, CPA.7.021, CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009, CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015, CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024, CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047, CPA.7.049, and CPA.7.050 CHA.7.518; and
- b) a second antigen binding portion comprising:
- i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
  - ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody;
- wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086, CHA.9.547.18, CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059, CPA.9.083, CPA.9.086, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103, CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6, CHA.9.536.7, CHA.9.536.8, CHA.9.560.1, CHA.9.560.3, CHA.9.560.4, CHA.9.560.5, CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1, CHA.9.547.1, CHA.9.547.2, CHA.9.547.3,

CHA.9.547.4, CHA.9.547.6, CHA.9.547.7, CHA.9.547.8,  
CHA.9.547.9, CHA.9.547.13, CHA.9.541.1, CHA.9.541.3,  
CHA.9.541.4, CHA.9.541.5, CHA.9.541.6, CHA.9.541.7, and  
CHA.9.541.8.

**[0019]** In some examples, the first antigen binding portion comprises:

- i. a first heavy chain comprising VH-CH1-hinge-CH2-CH3; and
- ii. a first light chain comprising VL-CL, wherein the CL is the constant domain of either a kappa or lambda antibody.

**[0020]** In some examples, the first heavy chain CH3 comprises the amino acid substitutions S354C, E356D, M358L, and T366W.

**[0021]** In some examples, the CL is kappa.

**[0022]** In some examples, the second antigen binding portion comprises:

- i. a second heavy chain comprising HC-CL-hinge-CH2-CH3, wherein the CL is either kappa or lambda; and
- ii. a second light chain comprising VL-CH1.

**[0023]** In some examples, the second heavy chain CH3 comprises the amino acid substitutions Y349C, E356D, M358L, T366S, L368A, and Y407V.

**[0024]** In some examples, the CL is lambda.

**[0025]** In some examples, the CL is kappa.

**[0026]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and
- b) a second anti-TIGIT antigen binding portion comprising:
  - i. a second heavy chain variable region comprising CPA.9.086 VH (EVQLVETGGGLIQPGRSLRLSCAASGFTFSSYAMHWVRQAPG KGLEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS; SEQ ID NO:1634); and
  - ii. a second light chain variable region comprising CPA.9.086 VL (QSALTQPRSASGNPQQRVTISCSGSSSNMGRRPVNWYQQIPGT APKLLIYSQNQRPSGVPDRFSGSQSGTSASLTISGLQSEDEAEYF CAVWDDIGRVLQLGGGTQLAVL; SEQ ID NO:1639).

**[0027]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- c) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and

- d) a second anti-TIGIT antigen binding portion comprising:
  - i. a second heavy chain variable region comprising CPA.9.547.18 VH (EVQLVESGGGLVQP~~GG~~SLRLSCAASGFTFSSYIMSWVRQAPGK GLEWVATISGGSKGQYYADSVKGRFTISRDN SKNTLYLQMNSL RAEDTAVYYCAKWLLSY~~Y~~AMDYWGQGT LVTVSS; SEQ ID NO:1664); and
  - ii. a second light chain variable region comprising CPA.9.547.18 VL (DIQMTQSPSSLSASVGDRITITCRASQSM~~AI~~WLSWYQQKPGKA PKLLIYKASKSHTGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYC QQGQSY~~PY~~TFGQGTKLEIK; SEQ ID NO:1668).

**[0028]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.1 VH (QVQLVQSGAEVKKPGASVKV~~S~~CKASGYTFTDYNINWVRQAP GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL SSLRSED~~T~~AVYYCAREDKTARNAMDYWGQGT LVTVSS; SEQ ID NO:1539); and
  - ii. a first light chain variable region comprising CHA.7.518.1 VL (DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKA PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYC QHFWGTPYTFGQGTKLEIK; SEQ ID NO:1544); and
- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.

**[0029]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.4 VH (QVQLVQSGAEVKKPGASVKV~~S~~CKASGYTFTDYNINWVRQAP GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL SSLRSED~~T~~AVYYCAREDKTARNAMDYWGQGT LVTVSS; SEQ ID NO:3179); and
  - ii. a first light chain variable region comprising CHA.7.518.4 VL (DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKA PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTIS SLQPEDFATYYC QHFWGTPYTFGQGTKLEIK; SEQ ID NO:3180); and
- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.

**[0030]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.1 VH (QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAP GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL SSLRSEDVAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ ID NO:1539); and
  - ii. a first light chain variable region comprising CHA.7.518.1 (DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKA PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYC QHFWGTPYTFGGQGTKLEIK; SEQ ID NO:1544); and
- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising
  - i. a first heavy chain variable region comprising CPA.9.086 VH (EVQLVETGGGLIQPGRSLRLSCAASGFTFSSYAMHWVRQAPG KGLEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCARDPLPLHYGMDVWGQGTTVTVSS; SEQ ID NO:1634); and
  - ii. a first light chain variable region comprising CPA.9.086 VL (QSALTQPRSASGNPGRVTISCSGSSSNMGRRPVNWYQQIPGT APKLLIYSQNQRPSGVPDRFSGSQSGTSASLTISGLQSEDEAEYF CAVWDDIGRVLQLGGGTQLAVL; SEQ ID NO: 1639).

**[0031]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.4 VH (QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAP GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL SSLRSEDVAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ ID NO:3179); and
  - ii. a first light chain variable region comprising CHA.7.518.4 VL (DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKA PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYC QHFWGTPYTFGGQGTKLEIK; SEQ ID NO:3180); and
- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:
  - i. a first heavy chain variable region comprising CPA.9.086 VH (EVQLVETGGGLIQPGRSLRLSCAASGFTFSSYAMHWVRQAPG KGLEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCARDPLPLHYGMDVWGQGTTVTVSS; SEQ ID NO:1634); and

- ii. a first light chain variable region comprising CPA.9.086 VL  
(QSALTQPRSASGNPGQRVTISCSGSSSNMGRRPVNWYQQIPGT  
APKLLIYSQNQRPSGVPDRFSGSQSGTSASLTISGLQSEDEAEYF  
CAVWDDIGRVLQLGGGTQLAVL; SEQ ID NO:1639).

**[0032]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.1  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAP  
GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL  
SSLRSEDVAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ  
ID NO: 1539); and
  - ii. a first light chain variable region comprising CHA.7.518.1 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKA  
PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYC  
QHFWGTPYTFGGGTKLEIK; SEQ ID NO: 1544); and
- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.9.547.18 HC  
(EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGK  
GLEWVATISGSGSKGQYYADSVKGRFTISRDN SKNTLYLQMNSL  
RAEDTAVYYCAKWLLSYAMDYWGQGTLVTVSS; SEQ ID  
NO: 1664); and
  - ii. a first light chain variable region comprising CHA.9.547.18 VL  
(DIQMTQSPSSLSASVGDRITITCRASQSMALWSWYQQKPGKA  
PKLLIYKASKSHTGVPSRFSGSGSGTDFTLTISLQPEDFATYYC  
QQGQSYPTTFGGGTKLEIK; SEQ ID NO: 1668).

**[0033]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody comprises:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.4 VH  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAP  
GQGLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMEL  
SSLRSEDVAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ  
ID NO:3179); and
  - ii. a first light chain variable region comprising CHA.7.518.4 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKA  
PKLLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYC  
QHFWGTPYTFGGGTKLEIK; SEQ ID NO:3180); and

- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.9.547.18 HC (EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGK GLEWVATISGGSKGQYYADSVKGRFTISRDN SKNTLYLQMNSL RAEDTAVYYCAKWLLSYAMDYWGQGT LVT VSS (SEQ ID NO: 1664); and
  - ii. a first light chain variable region comprising CHA.9.547.18 VL (DIQMTQSPSSLSASVGDRITITCRASQSMAIWLSWYQQKPGKA PKLLIYKASKSHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQGQSYPTYTFGQGGTKLEIK; SEQ ID NO: 1668).

**[0034]** In some aspects, the anti-PVRIG/anti-TIGIT bispecific antibody is a humanized antibody.

**[0035]** In some aspects, the present disclosure provides a composition comprising an anti-PVRIG/anti-TIGIT bispecific antibody as described herein.

**[0036]** In another aspect, the present disclosure refers to a nucleic acid composition comprising:

- a) a first nucleic acid encoding a first heavy chain or heavy chain variable domain as described herein;
- b) a second nucleic acid encoding a first light chain or light chain variable domain as described herein;
- c) a third nucleic acid encoding a second heavy chain or heavy chain variable domain as described herein; and
- d) a fourth nucleic acid encoding a second light chain or light chain variable domain as described herein.

**[0037]** In some aspects, the present disclosure provides an expression vector composition comprising:

- a) a first expression vector comprising the first nucleic acid as described herein;
- b) a second expression vector comprising the second nucleic acid as described herein;
- c) a third expression vector comprising the third nucleic acid as described herein; and
- d) a fourth expression vector comprising the fourth nucleic acid as described herein.

**[0038]** In some aspects, the present disclosure provides an expression vector composition comprising:

- a) a first expression vector comprising the first and second nucleic acids as described herein; and
- b) a second expression vector comprising the third and fourth nucleic acids as described herein.

**[0039]** In some aspects, the present disclosure provides a host cell comprising the expression vector composition as described herein.

**[0040]** In some aspects, the present disclosure provides a method of making an anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) culturing the host cell as described herein under conditions wherein the antibody is expressed; and
- b) recovering the antibody.

**[0041]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating T cells of the cancer a patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating T cells of a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient, wherein a subset of the T cells of the patient are activated.

**[0042]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of the cancer a patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated. In some examples, the present disclosure provides a method of activating cytotoxic T cells (CTLs) of a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient, wherein a subset of the CTLs of the patient are activated.

**[0043]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating NK cells of a-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the NK cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating NK cells of a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient, wherein a subset of the NK cells of the patient are activated.

**[0044]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of a-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are to be activated. In some examples, the

present disclosure provides a method of activating  $\gamma\delta$  T cells of a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are activated.

**[0045]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating Th1 cells of a-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating Th1 cells of a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient, wherein a subset of the Th1 cells of the patient are activated.

**[0046]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a-the cancer patient, wherein said bispecific antibody is to be administered to the patient. In some examples, the present disclosure provides a method of decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient.

**[0047]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a-the cancer patient, wherein said bispecific antibody is to be administered to the patient. In some examples, the present disclosure provides a method of increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a patient comprising administering the anti-PVRIG/anti-TIGIT bispecific antibody as described herein to the patient.

**[0048]** In some aspects, the present disclosure provides a use of the anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for treating cancer in a patient, wherein said bispecific antibody is to be administered to the patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering the anti-PVRIG/anti-TIGIT antibody as described herein to the patient.

**[0049]** In some examples, the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

**[0050]** In some examples, the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

**[0051]** In another aspect, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising: a) a first antigen binding portion comprising an anti-PVRIG antigen binding portion comprising: i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody; wherein the anti-PVRIG antigen binding portion is selected from the group consisting of CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883), CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915), CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947), CHA.7.538\_1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979), CHA.7.538\_2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987), CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819), CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827), CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835), CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843), CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851), CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ ID NO:859), CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862, and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865, vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867), CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of SEQ ID NO:870, and vhCDR3 of

SEQ ID NO:871; and vLCDR1 of SEQ ID NO:873, vLCDR2 of SEQ ID NO:874, and vLCDR3 of SEQ ID NO:875), CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886, and vhCDR3 of SEQ ID NO:887; and vLCDR1 of SEQ ID NO:889, vLCDR2 of SEQ ID NO:890, and vLCDR3 of SEQ ID NO:891), CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894, and vhCDR3 of SEQ ID NO:895; and vLCDR1 of SEQ ID NO:897, vLCDR2 of SEQ ID NO:898, and vLCDR3 of SEQ ID NO:899), CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902, and vhCDR3 of SEQ ID NO:903; and vLCDR1 of SEQ ID NO:905, vLCDR2 of SEQ ID NO:906, and vLCDR3 of SEQ ID NO:907), CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918, and vhCDR3 of SEQ ID NO:919; and vLCDR1 of SEQ ID NO:921, vLCDR2 of SEQ ID NO:922, and vLCDR3 of SEQ ID NO:923), CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926, and vhCDR3 of SEQ ID NO:927; and vLCDR1 of SEQ ID NO:929, vLCDR2 of SEQ ID NO:930, and vLCDR3 of SEQ ID NO:931), CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934, and vhCDR3 of SEQ ID NO:935; and vLCDR1 of SEQ ID NO:937, vLCDR2 of SEQ ID NO:938, and vLCDR3 of SEQ ID NO:939), CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950, and vhCDR3 of SEQ ID NO:951; and vLCDR1 of SEQ ID NO:953, vLCDR2 of SEQ ID NO:954, and vLCDR3 of SEQ ID NO:955), CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958, and vhCDR3 of SEQ ID NO:959; and vLCDR1 of SEQ ID NO:961, vLCDR2 of SEQ ID NO:962, and vLCDR3 of SEQ ID NO:963), CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966, and vhCDR3 of SEQ ID NO:967; and vLCDR1 of SEQ ID NO:969, vLCDR2 of SEQ ID NO:970, and vLCDR3 of SEQ ID NO:971), CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990, and vhCDR3 of SEQ ID NO:991; and vLCDR1 of SEQ ID NO:993, vLCDR2 of SEQ ID NO:994, and vLCDR3 of SEQ ID NO:995), CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998, and vhCDR3 of SEQ ID NO:999; and vLCDR1 of SEQ ID NO:1001, vLCDR2 of SEQ ID NO:1002, and vLCDR3 of SEQ ID NO:1003), CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID NO:1006, and vhCDR3 of SEQ ID NO:1007; and vLCDR1 of SEQ ID NO:1009, vLCDR2 of SEQ ID NO:1010, and vLCDR3 of SEQ ID NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vLCDR1 of SEQ ID NO:1017, vLCDR2 of SEQ ID NO:1018, and vLCDR3 of SEQ ID NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vLCDR1 of SEQ ID NO:1025, vLCDR2 of SEQ ID NO:1026, and vLCDR3 of SEQ ID NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vLCDR1 of SEQ ID NO:1033, vLCDR2 of SEQ ID NO:1034, and vLCDR3 of SEQ ID NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vLCDR1 of SEQ ID NO:1041, vLCDR2 of SEQ ID NO:1042, and vLCDR3 of SEQ ID NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vLCDR1 of SEQ ID NO:1049, vLCDR2 of SEQ ID NO:1050, and vLCDR3 of SEQ ID NO:1051), CHA.7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of SEQ ID NO:1551, and vhCDR3 of SEQ ID NO:1552; and vLCDR1 of SEQ ID NO:1555, vLCDR2 of SEQ ID NO:1556, and vLCDR3 of SEQ ID NO:1557),

CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ ID NO:320, and vhCDR3 of SEQ ID NO:321; and vlCDR1 of SEQ ID NO:324, vlCDR2 of SEQ ID NO:325, and vlCDR3 of SEQ ID NO:326), CPA.7.001 (vhCDR1 of SEQ ID NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vlCDR1 of SEQ ID NO:174, vlCDR2 of SEQ ID NO:175, and vlCDR3 of SEQ ID NO:176), CPA.7.003 (vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID NO:181; and vlCDR1 of SEQ ID NO:184, vlCDR2 of SEQ ID NO:185, and vlCDR3 of SEQ ID NO:186), CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and vhCDR3 of SEQ ID NO:191; and vlCDR1 of SEQ ID NO:194, vlCDR2 of SEQ ID NO:195, and vlCDR3 of SEQ ID NO:196), CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vlCDR1 of SEQ ID NO:204, vlCDR2 of SEQ ID NO:205, and vlCDR3 of SEQ ID NO:206), CPA.7.008 (vhCDR1 of SEQ ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vlCDR1 of SEQ ID NO:214, vlCDR2 of SEQ ID NO:215, and vlCDR3 of SEQ ID NO:216), CPA.7.009 (vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID NO:221; and vlCDR1 of SEQ ID NO:224, vlCDR2 of SEQ ID NO:225, and vlCDR3 of SEQ ID NO:226), CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and vhCDR3 of SEQ ID NO:231; and vlCDR1 of SEQ ID NO:234, vlCDR2 of SEQ ID NO:235, and vlCDR3 of SEQ ID NO:236), CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vlCDR1 of SEQ ID NO:244, vlCDR2 of SEQ ID NO:245, and vlCDR3 of SEQ ID NO:246), CPA.7.012 (vhCDR1 of SEQ ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vlCDR1 of SEQ ID NO:254, vlCDR2 of SEQ ID NO:255, and vlCDR3 of SEQ ID NO:256), CPA.7.013 (vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID NO:261; and vlCDR1 of SEQ ID NO:264, vlCDR2 of SEQ ID NO:265, and vlCDR3 of SEQ ID NO:266), CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270, and vhCDR3 of SEQ ID NO:271; and vlCDR1 of SEQ ID NO:274, vlCDR2 of SEQ ID NO:275, and vlCDR3 of SEQ ID NO:276), CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of SEQ ID NO:280, and vhCDR3 of SEQ ID NO:281; and vlCDR1 of SEQ ID NO:284, vlCDR2 of SEQ ID NO:285, and vlCDR3 of SEQ ID NO:286), CPA.7.017 (vhCDR1 of SEQ ID NO:289, vhCDR2 of SEQ ID NO:290, and vhCDR3 of SEQ ID NO:291; and vlCDR1 of SEQ ID NO:294, vlCDR2 of SEQ ID NO:295, and vlCDR3 of SEQ ID NO:296), CPA.7.018 (vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300, and vhCDR3 of SEQ ID NO:301; and vlCDR1 of SEQ ID NO:304, vlCDR2 of SEQ ID NO:305, and vlCDR3 of SEQ ID NO:306), CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310, and vhCDR3 of SEQ ID NO:311; and vlCDR1 of SEQ ID NO:314, vlCDR2 of SEQ ID NO:315, and vlCDR3 of SEQ ID NO:316), CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of SEQ ID NO:330, and vhCDR3 of SEQ ID NO:331; and vlCDR1 of SEQ ID NO:334, vlCDR2 of SEQ ID NO:335, and vlCDR3 of SEQ ID NO:336), CPA.7.023 (vhCDR1 of SEQ ID NO:339, vhCDR2 of SEQ ID NO:340, and vhCDR3 of SEQ ID NO:341; and vlCDR1 of SEQ ID NO:344, vlCDR2 of SEQ ID NO:345, and vlCDR3 of SEQ ID NO:346), CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350, and vhCDR3 of SEQ ID NO:351; and vlCDR1 of SEQ ID NO:354, vlCDR2 of SEQ ID NO:355, and vlCDR3 of SEQ ID NO:356), CPA.7.033

(vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360, and vhCDR3 of SEQ ID NO:361; and vlCDR1 of SEQ ID NO:364, vlCDR2 of SEQ ID NO:365, and vlCDR3 of SEQ ID NO:366), CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370, and vhCDR3 of SEQ ID NO:371; and vlCDR1 of SEQ ID NO:374, vlCDR2 of SEQ ID NO:375, and vlCDR3 of SEQ ID NO:376), CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380, and vhCDR3 of SEQ ID NO:381; and vlCDR1 of SEQ ID NO:384, vlCDR2 of SEQ ID NO:385, and vlCDR3 of SEQ ID NO:386), CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390, and vhCDR3 of SEQ ID NO:391; and vlCDR1 of SEQ ID NO:394, vlCDR2 of SEQ ID NO:395, and vlCDR3 of SEQ ID NO:396), CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400, and vhCDR3 of SEQ ID NO:401; and vlCDR1 of SEQ ID NO:404, vlCDR2 of SEQ ID NO:405, and vlCDR3 of SEQ ID NO:406), CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410, and vhCDR3 of SEQ ID NO:411; and vlCDR1 of SEQ ID NO:414, vlCDR2 of SEQ ID NO:415, and vlCDR3 of SEQ ID NO:416), CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420, and vhCDR3 of SEQ ID NO:421; and vlCDR1 of SEQ ID NO:424, vlCDR2 of SEQ ID NO:425, and vlCDR3 of SEQ ID NO:426), and CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430, and vhCDR3 of SEQ ID NO:431; and vlCDR1 of SEQ ID NO:434, vlCDR2 of SEQ ID NO:435, and vlCDR3 of SEQ ID NO:436); and b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain, wherein the anti-TIGIT antigen binding domain is from an antibody as provided in Figures 24 and 41, and in particular Figure 24A-24EE.

**[0051a]** In some aspectsexamples, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG antigen binding portion comprising:
  - i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
  - ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody;
 wherein the anti-PVRIG antigen binding portion is selected from the group consisting of CPA.7.021, CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009, CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015, CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024, CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047, CPA.7.049, CPA.7.050, CHA.7.502, CHA.7.503, CHA.7.506, CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514, CHA.7.516, CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522, CHA.7.524, CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530, CHA.7.534, CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2, CHA.7.543, CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547,

CHA.7.548, CHA.7.549, CHA.7.550, CHA.7.518.1; CHA.7.538.1.2 and CHA.7.518.4; and

- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain, wherein the anti-TIGIT antigen binding domain is from an antibody as provided in Figures 24 and 41, and in particular Figure 24A-24EE.

**[0052]** In yet another aspect, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising: a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain wherein the anti-PVRIG antigen binding domain is from an antibody as provided in Figure 35; and b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain comprising: i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody; wherein the anti-TIGIT antigen binding domain is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vlCDR1 of SEQ ID NO:1640, vlCDR2 of SEQ ID NO:1641, and vlCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vlCDR1 of SEQ ID NO:1669, vlCDR2 of SEQ ID NO:1670, and vlCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vlCDR1 of SEQ ID NO:1678, vlCDR2 of SEQ ID NO:1679, and vlCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vlCDR1 of SEQ ID NO:1688, vlCDR2 of SEQ ID NO:1689, and vlCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vlCDR1 of SEQ ID NO:1698, vlCDR2 of SEQ ID NO:1699, and vlCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vlCDR1 of SEQ ID NO:1708, vlCDR2 of SEQ ID NO:1709, and vlCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vlCDR1 of SEQ ID NO:1718, vlCDR2 of SEQ ID NO:1719, and vlCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vlCDR1 of SEQ ID NO:1728, vlCDR2 of SEQ ID NO:1729, and vlCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vlCDR1 of SEQ ID NO:1748, vlCDR2 of SEQ ID NO:1749, and vlCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vlCDR1 of SEQ ID NO:1758, vlCDR2 of SEQ ID NO:1759, and vlCDR3 of SEQ ID NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vlCDR1 of SEQ ID NO:1768, vlCDR2 of SEQ ID NO:1769, and vlCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vlCDR1 of SEQ ID NO:1778, vlCDR2 of SEQ ID NO:1779, and vlCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of

SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vlCDR1 of SEQ ID NO:1808, vlCDR2 of SEQ ID NO:1809, and vlCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vlCDR1 of SEQ ID NO:1818, vlCDR2 of SEQ ID NO:1819, and vlCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and vhCDR3 of SEQ ID NO:1825; and vlCDR1 of SEQ ID NO:1828, vlCDR2 of SEQ ID NO:1829, and vlCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vlCDR1 of SEQ ID NO:1838, vlCDR2 of SEQ ID NO:1839, and vlCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vlCDR1 of SEQ ID NO:1848, vlCDR2 of SEQ ID NO:1849, and vlCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vlCDR1 of SEQ ID NO:1858, vlCDR2 of SEQ ID NO:1859, and vlCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vlCDR1 of SEQ ID NO:1868, vlCDR2 of SEQ ID NO:1869, and vlCDR3 of SEQ ID NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vlCDR1 of SEQ ID NO:1878, vlCDR2 of SEQ ID NO:1879, and vlCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vlCDR1 of SEQ ID NO:1888, vlCDR2 of SEQ ID NO:1889, and vlCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vlCDR1 of SEQ ID NO:1898, vlCDR2 of SEQ ID NO:1899, and vlCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vlCDR1 of SEQ ID NO:1908, vlCDR2 of SEQ ID NO:1909, and vlCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vlCDR1 of SEQ ID NO:1918, vlCDR2 of SEQ ID NO:1919, and vlCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vlCDR1 of SEQ ID NO:1928, vlCDR2 of SEQ ID NO:1929, and vlCDR3 of SEQ ID NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vlCDR1 of SEQ ID NO:1938, vlCDR2 of SEQ ID NO:1939, and vlCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vlCDR1 of SEQ ID NO:1948, vlCDR2 of SEQ ID NO:1949, and vlCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vlCDR1 of SEQ ID NO:1958, vlCDR2 of SEQ ID NO:1959, and vlCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vlCDR1 of SEQ ID NO:1968, vlCDR2 of SEQ ID NO:1969, and vlCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vlCDR1 of SEQ ID NO:1978, vlCDR2 of SEQ ID NO:1979, and vlCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and

vhCDR3 of SEQ ID NO:1985; and vlCDR1 of SEQ ID NO:1988, vlCDR2 of SEQ ID NO:1989, and vlCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vlCDR1 of SEQ ID NO:1998, vlCDR2 of SEQ ID NO:1999, and vlCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID NO:2005; and vlCDR1 of SEQ ID NO:2008, vlCDR2 of SEQ ID NO:2009, and vlCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vlCDR1 of SEQ ID NO:2018, vlCDR2 of SEQ ID NO:2019, and vlCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vlCDR1 of SEQ ID NO:2028, vlCDR2 of SEQ ID NO:2029, and vlCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vlCDR1 of SEQ ID NO:1660, vlCDR2 of SEQ ID NO:1661, and vlCDR3 of SEQ ID NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vlCDR1 of SEQ ID NO:2038, vlCDR2 of SEQ ID NO:2039, and vlCDR3 of SEQ ID NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vlCDR1 of SEQ ID NO:2048, vlCDR2 of SEQ ID NO:2049, and vlCDR3 of SEQ ID NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vlCDR1 of SEQ ID NO:2058, vlCDR2 of SEQ ID NO:2059, and vlCDR3 of SEQ ID NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vlCDR1 of SEQ ID NO:2068, vlCDR2 of SEQ ID NO:2069, and vlCDR3 of SEQ ID NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vlCDR1 of SEQ ID NO:2078, vlCDR2 of SEQ ID NO:2079, and vlCDR3 of SEQ ID NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vlCDR1 of SEQ ID NO:2088, vlCDR2 of SEQ ID NO:2089, and vlCDR3 of SEQ ID NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vlCDR1 of SEQ ID NO:2098, vlCDR2 of SEQ ID NO:2099, and vlCDR3 of SEQ ID NO:2100).

**[0052a]** In some aspectsexamples, the present disclosure provides an anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain wherein the anti-PVRIG antigen binding domain is from an antibody as provided in Figure 35; and
- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain comprising:
  - i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
  - ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody;

wherein the anti-TIGIT antigen binding domain is selected from the group consisting of CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059, CPA.9.083, CPA.9.086, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103, CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6, CHA.9.536.7, CHA.9.536.8, CHA.9.560.1, CHA.9.560.3, CHA.9.560.4, CHA.9.560.5, CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1, CHA.9.547.1, CHA.9.547.2, CHA.9.547.3, CHA.9.547.4, CHA.9.547.6, CHA.9.547.7, CHA.9.547.8, CHA.9.547.9, CHA.9.547.13, CHA.9.541.1, CHA.9.541.3, CHA.9.541.4, CHA.9.541.5, CHA.9.541.6, CHA.9.541.7, CHA.9.541.8, and CHA.9.547.18.

**[0053]** In some aspects, the present disclosure provides an anti-PVRIG antibody comprising:

i) a heavy chain or heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from the following sequence:

QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGGLEWMGYIYPYIGGSGYAQKFQG  
RVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREDKTARNAMDYWGQGTLLTVSS (SEQ ID  
NO:3179) ,

and

ii) a light chain or light chain variable domain comprising the vlCDR1, vlCDR2, vlCDR3 from the following sequence:

DIQMTQSPSSLSASVGDRTITCRVSENIDVLAWYQQKPGKAPKLLIYEATNLAEGVPSRFSGSG  
SGTDFTLTITSSLPEDFATYYCQHFWGTPYTFGQGTKLEIK (SEQ ID NO:3180) .

**[0054]** In some aspects, the present disclosure provides an anti-TIGIT antibody comprising:

i) a heavy chain or heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from the following sequence:

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGKGLEWVATISGGSKGQYYADSVKG  
RFTISRDNKNTLYLQMNSLRAEDTAVYYCAKWLLSYAMDYWGQGTLLTVSS (SEQ ID  
NO:1664) ,

and

ii) a light chain or light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from the following sequence:

DIQMTQSPSSLSASVGDRTITCRASQSMALWSWYQQKPGKAPKLLIYKASKSHTGVPSRFSGSG  
SGTDFTLTITSSLPEDFATYYCQQGQSYPTFGQGTKLEIK (SEQ ID NO:1668) .

**[0055]** In some examples, the anti-PVRIG antibody comprises:

- a) a heavy chain comprising CHA.7.518.4 VH  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQGLE  
WMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRSED  
TAVYYCAREDKTARNAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSE  
STAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV  
VTVPSSSLGKTYTCNVDPKPSNTKVDKRVESKYGPPCPPCPAPEFLG  
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV  
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS  
IEKTISKAKGQPREPQVYTLPPCQDELTKNQVSLWCLVKGFYPSDIAV  
EWESNGQPENNYKTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS  
VMHEALHNHYTQKSLSLSPGK; SEQ ID NO:3175); and
- b) a light chain comprising CHA.7.518.4 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPKLLI  
YEATNLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHFHWGTPYT  
FGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV  
QWKVDNALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKVYA  
CEVTHQGLSSPVTKSFNRGEC ; SEQ ID NO: 3362).

**[0056]** In some aspects, the present disclosure provides a composition comprising an anti-PVRIG antibody according as described herein.

**[0057]** In some aspects, the present disclosure provides a nucleic acid composition comprising:

- i) a first nucleic acid encoding a heavy chain or heavy chain variable domain as described herein; and
- ii) a second nucleic acid encoding a light chain or light chain variable domain as described herein.

**[0058]** In some aspects, the present disclosure provides a composition comprising an anti-TIGIT antibody as described herein.

**[0059]** In some examples, the present disclosure provides a nucleic acid composition comprising:

- i) a first nucleic acid encoding a heavy chain or heavy chain variable domain as described herein; and
- ii) a second nucleic acid encoding a light chain or light chain variable domain as described herein.

**[0060]** In some aspects, the present disclosure provides an expression vector composition comprising:

- i) a first expression vector comprising the first nucleic acid as described herein; and
- ii) a second expression vector comprising the second nucleic acid as described herein.

[0061] In some other aspects, the present disclosure refers to an expression vector comprising:

- i) the first nucleic acid as described herein; and
- ii) the second nucleic acid as described herein.

[0062] In some aspects, the present disclosure provides an expression vector composition comprising:

- i) a first expression vector comprising the first nucleic acid as described herein; and
- ii) a second expression vector comprising the second nucleic acid as described herein.

[0063] In some aspects, the present disclosure provides an expression vector comprising:

- i) the first nucleic acid as described herein; and
- ii) the second nucleic acid as described herein.

[0064] In some aspects, the present disclosure provides a host cell comprising the expression vector or vector composition as described herein.

[0065] In some aspects, the present disclosure provides a method of making an anti-PVRIG or anti-TIGIT antibody comprising:

- i) culturing the host cell as described herein under conditions wherein the antibody is expressed; and
- ii) recovering the antibody.

[0066] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating T cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating T cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the T cells of the patient are activated.

[0067] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated. In some examples, the present disclosure provides a method of activating cytotoxic T cells (CTLs) of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the CTLs of the patient are activated.

[0068] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating NK cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the NK cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating NK cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the NK cells of the patient are activated.

[0069] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating  $\gamma\delta$  T cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are activated.

[0070] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating Th1 cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating Th1 cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the Th1 cells of the patient are activated.

[0071] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a-the cancer patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient.

[0072] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a the cancer patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient.

[0073] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating cancer in a patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient.

**[0074]** In some examples, the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

**[0075]** In some examples, the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

**[0076]** In some aspects, the present disclosure provides a use of an anti-PVRIG/anti-TIGIT bispecific antibody as disclosed herein in the manufacture of a medicament for use in combination therapy for treating cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a combination therapy comprising an anti-PVRIG/anti-TIGIT bispecific antibody according to as described herein.

**[0077]** In some aspects, the present disclosure provides a use of an anti-PVRIG antibody as disclosed herein and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a combination therapy comprising an anti-PVRIG antibody as described herein and an anti-PD-1 antibody.

**[0078]** In some aspects, the present disclosure provides a use of an anti-TIGIT antibody as disclosed herein and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab and nivolumab.

**[0079]** In some aspects, the present disclosure provides a use of an anti-TIGIT antibody as disclosed herein and an anti-PVRIG antibody as disclosed herein in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a combination therapy comprising an anti-TIGIT antibody as described herein and an anti-PD-1 antibody.

**[0080]** In some aspects, the present disclosure provides a use of an anti-TIGIT antibody as disclosed herein, an anti-PVRIG antibody, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab and nivolumab.

**[0081]** In some aspects, the present disclosure provides a use of an anti-TIGIT antibody as disclosed herein and an anti-PVRIG antibody as disclosed herein in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a combination therapy comprising an anti-TIGIT antibody as described herein and an anti-PVRIG antibody as described herein.

**[0082]** In some aspects, the present disclosure provides a use of an anti-TIGIT antibody as disclosed herein, an anti-PVRIG antibody, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a triple combination therapy comprising an anti-TIGIT antibody as described herein, an anti-PVRIG antibody, and an anti-PD-1 antibody.

**[0083]** In some aspects, the present disclosure provides a use of an anti-TIGIT, an anti-PVRIG antibody as disclosed herein, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a triple combination therapy comprising an anti-TIGIT, an anti-PVRIG antibody as described herein, and an anti-PD-1 antibody.

**[0084]** In some aspects, the present disclosure provides a use of an anti-TIGIT as disclosed herein, an anti-PVRIG antibody as disclosed herein, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat

cancer in a patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering a triple combination therapy comprising an anti-TIGIT as described herein, an anti-PVRIG antibody as described herein, and an anti-PD-1 antibody.

[0085] In some examples, the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab and nivolumab.

[0086] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating T cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated. In some examples, the present disclosure provides a method of activating T cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the T cells of the patient are activated.

[0087] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated. In some examples, the present disclosure provides a method of activating cytotoxic T cells (CTLs) of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the CTLs of the patient are activated.

[0088] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient is to be activated. In some examples, the present disclosure provides a method of activating  $\gamma\delta$  T cells of a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are activated.

[0089] In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by activating Th1 cells of a-the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient is to be activated. In some examples, the present disclosure provides a method of activating Th1 cells of a patient comprising administering the anti-

PVRIG or anti-TIGIT antibody as described herein to the patient, wherein a subset of the Th1 cells of the patient are activated.

**[0090]** In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in ~~a~~the cancer patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient.

**[0091]** In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in ~~a~~the cancer patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a patient comprising administering the anti-PVRIG or anti-TIGIT as described herein to the patient.

**[0092]** In some aspects, the present disclosure provides a use of the anti-PVRIG or anti-TIGIT antibody as disclosed herein in the manufacture of a medicament for treating cancer in a patient, wherein said antibody is to be administered to the patient. In some examples, the present disclosure provides a method of treating cancer in a patient comprising administering the anti-PVRIG or anti-TIGIT antibody as described herein to the patient.

**[0093]** In some examples, the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

**[0094]** In some examples, the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

## CLAIMS

What is claimed:

1. An anti-PVRIG/anti-TIGIT bispecific antibody that monovalently binds a human PVRIG and monovalently binds TIGIT for use in therapy.
2. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
  - a) a first antigen binding portion comprising:
    - i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
    - ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody;

wherein the anti-PVRIG antibody is selected from the group consisting of

CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883), CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915), CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947), CHA.7.538 1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979),

CHA.7.538 2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987),  
CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819),  
CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827),  
CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835),  
CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843),  
CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851),  
CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ ID NO:859),  
CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862, and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865, vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867),  
CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of SEQ ID NO:870, and vhCDR3 of SEQ ID NO:871; and vlCDR1 of SEQ ID NO:873, vlCDR2 of SEQ ID NO:874, and vlCDR3 of SEQ ID NO:875),  
CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886, and vhCDR3 of SEQ ID NO:887; and vlCDR1 of SEQ ID NO:889, vlCDR2 of SEQ ID NO:890, and vlCDR3 of SEQ ID NO:891),  
CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894,

and vhCDR3 of SEQ ID NO:895; and vlCDR1 of SEQ ID NO:897,  
vlCDR2 of SEQ ID NO:898, and vlCDR3 of SEQ ID NO:899),  
CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902,  
and vhCDR3 of SEQ ID NO:903; and vlCDR1 of SEQ ID NO:905,  
vlCDR2 of SEQ ID NO:906, and vlCDR3 of SEQ ID NO:907),  
CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918,  
and vhCDR3 of SEQ ID NO:919; and vlCDR1 of SEQ ID NO:921,  
vlCDR2 of SEQ ID NO:922, and vlCDR3 of SEQ ID NO:923),  
CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926,  
and vhCDR3 of SEQ ID NO:927; and vlCDR1 of SEQ ID NO:929,  
vlCDR2 of SEQ ID NO:930, and vlCDR3 of SEQ ID NO:931),  
CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934,  
and vhCDR3 of SEQ ID NO:935; and vlCDR1 of SEQ ID NO:937,  
vlCDR2 of SEQ ID NO:938, and vlCDR3 of SEQ ID NO:939),  
CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950,  
and vhCDR3 of SEQ ID NO:951; and vlCDR1 of SEQ ID NO:953,  
vlCDR2 of SEQ ID NO:954, and vlCDR3 of SEQ ID NO:955),  
CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958,  
and vhCDR3 of SEQ ID NO:959; and vlCDR1 of SEQ ID NO:961,  
vlCDR2 of SEQ ID NO:962, and vlCDR3 of SEQ ID NO:963),  
CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966,  
and vhCDR3 of SEQ ID NO:967; and vlCDR1 of SEQ ID NO:969,  
vlCDR2 of SEQ ID NO:970, and vlCDR3 of SEQ ID NO:971),  
CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990,  
and vhCDR3 of SEQ ID NO:991; and vlCDR1 of SEQ ID NO:993,  
vlCDR2 of SEQ ID NO:994, and vlCDR3 of SEQ ID NO:995),  
CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998,  
and vhCDR3 of SEQ ID NO:999; and vlCDR1 of SEQ ID NO:1001,  
vlCDR2 of SEQ ID NO:1002, and vlCDR3 of SEQ ID NO:1003),  
CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID  
NO:1006, and vhCDR3 of SEQ ID NO:1007; and vlCDR1 of SEQ ID

NO:1009, vlCDR2 of SEQ ID NO:1010, and vlCDR3 of SEQ ID NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vlCDR1 of SEQ ID NO:1017, vlCDR2 of SEQ ID NO:1018, and vlCDR3 of SEQ ID NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vlCDR1 of SEQ ID NO:1025, vlCDR2 of SEQ ID NO:1026, and vlCDR3 of SEQ ID NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vlCDR1 of SEQ ID NO:1033, vlCDR2 of SEQ ID NO:1034, and vlCDR3 of SEQ ID NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vlCDR1 of SEQ ID NO:1041, vlCDR2 of SEQ ID NO:1042, and vlCDR3 of SEQ ID NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vlCDR1 of SEQ ID NO:1049, vlCDR2 of SEQ ID NO:1050, and vlCDR3 of SEQ ID NO:1051), CHA7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of SEQ ID NO:1551, and vhCDR3 of SEQ ID NO:1552; and vlCDR1 of SEQ ID NO:1555, vlCDR2 of SEQ ID NO:1556, and vlCDR3 of SEQ ID NO:1557), CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ ID NO:320, and vhCDR3 of SEQ ID NO:321; and vlCDR1 of SEQ ID NO:324, vlCDR2 of SEQ ID NO:325, and vlCDR3 of SEQ ID NO:326), CPA.7.001 (vhCDR1 of SEQ ID NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vlCDR1 of SEQ ID NO:174, vlCDR2 of SEQ ID NO:175, and vlCDR3 of SEQ ID NO:176), CPA.7.003 (vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID NO:181; and vlCDR1 of SEQ ID NO:184, vlCDR2 of SEQ ID NO:185, and vlCDR3 of SEQ ID NO:186), CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and vhCDR3 of SEQ ID NO:191; and vlCDR1 of SEQ ID NO:194, vlCDR2 of SEQ ID NO:195, and vlCDR3 of SEQ ID NO:196),

CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vlCDR1 of SEQ ID NO:204, vlCDR2 of SEQ ID NO:205, and vlCDR3 of SEQ ID NO:206),  
CPA.7.008 (vhCDR1 of SEQ ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vlCDR1 of SEQ ID NO:214, vlCDR2 of SEQ ID NO:215, and vlCDR3 of SEQ ID NO:216),  
CPA.7.009 (vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID NO:221; and vlCDR1 of SEQ ID NO:224, vlCDR2 of SEQ ID NO:225, and vlCDR3 of SEQ ID NO:226),  
CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and vhCDR3 of SEQ ID NO:231; and vlCDR1 of SEQ ID NO:234, vlCDR2 of SEQ ID NO:235, and vlCDR3 of SEQ ID NO:236),  
CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vlCDR1 of SEQ ID NO:244, vlCDR2 of SEQ ID NO:245, and vlCDR3 of SEQ ID NO:246),  
CPA.7.012 (vhCDR1 of SEQ ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vlCDR1 of SEQ ID NO:254, vlCDR2 of SEQ ID NO:255, and vlCDR3 of SEQ ID NO:256),  
CPA.7.013 (vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID NO:261; and vlCDR1 of SEQ ID NO:264, vlCDR2 of SEQ ID NO:265, and vlCDR3 of SEQ ID NO:266),  
CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270, and vhCDR3 of SEQ ID NO:271; and vlCDR1 of SEQ ID NO:274, vlCDR2 of SEQ ID NO:275, and vlCDR3 of SEQ ID NO:276),  
CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of SEQ ID NO:280, and vhCDR3 of SEQ ID NO:281; and vlCDR1 of SEQ ID NO:284, vlCDR2 of SEQ ID NO:285, and vlCDR3 of SEQ ID NO:286),  
CPA.7.017 (vhCDR1 of SEQ ID NO:289, vhCDR2 of SEQ ID NO:290, and vhCDR3 of SEQ ID NO:291; and vlCDR1 of SEQ ID NO:294, vlCDR2 of SEQ ID NO:295, and vlCDR3 of SEQ ID NO:296),  
CPA.7.018 (vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300,

and vhCDR3 of SEQ ID NO:301; and vlCDR1 of SEQ ID NO:304,  
vlCDR2 of SEQ ID NO:305, and vlCDR3 of SEQ ID NO:306),  
CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310,  
and vhCDR3 of SEQ ID NO:311; and vlCDR1 of SEQ ID NO:314,  
vlCDR2 of SEQ ID NO:315, and vlCDR3 of SEQ ID NO:316),  
CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of SEQ ID NO:330,  
and vhCDR3 of SEQ ID NO:331; and vlCDR1 of SEQ ID NO:334,  
vlCDR2 of SEQ ID NO:335, and vlCDR3 of SEQ ID NO:336),  
CPA.7.023 (vhCDR1 of SEQ ID NO:339, vhCDR2 of SEQ ID NO:340,  
and vhCDR3 of SEQ ID NO:341; and vlCDR1 of SEQ ID NO:344,  
vlCDR2 of SEQ ID NO:345, and vlCDR3 of SEQ ID NO:346),  
CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350,  
and vhCDR3 of SEQ ID NO:351; and vlCDR1 of SEQ ID NO:354,  
vlCDR2 of SEQ ID NO:355, and vlCDR3 of SEQ ID NO:356),  
CPA.7.033 (vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360,  
and vhCDR3 of SEQ ID NO:361; and vlCDR1 of SEQ ID NO:364,  
vlCDR2 of SEQ ID NO:365, and vlCDR3 of SEQ ID NO:366),  
CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370,  
and vhCDR3 of SEQ ID NO:371; and vlCDR1 of SEQ ID NO:374,  
vlCDR2 of SEQ ID NO:375, and vlCDR3 of SEQ ID NO:376),  
CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380,  
and vhCDR3 of SEQ ID NO:381; and vlCDR1 of SEQ ID NO:384,  
vlCDR2 of SEQ ID NO:385, and vlCDR3 of SEQ ID NO:386),  
CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390,  
and vhCDR3 of SEQ ID NO:391; and vlCDR1 of SEQ ID NO:394,  
vlCDR2 of SEQ ID NO:395, and vlCDR3 of SEQ ID NO:396),  
CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400,  
and vhCDR3 of SEQ ID NO:401; and vlCDR1 of SEQ ID NO:404,  
vlCDR2 of SEQ ID NO:405, and vlCDR3 of SEQ ID NO:406),  
CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410,  
and vhCDR3 of SEQ ID NO:411; and vlCDR1 of SEQ ID NO:414,

vlCDR2 of SEQ ID NO:415, and vlCDR3 of SEQ ID NO:416),  
CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420,  
and vhCDR3 of SEQ ID NO:421; and vlCDR1 of SEQ ID NO:424,  
vlCDR2 of SEQ ID NO:425, and vlCDR3 of SEQ ID NO:426), and  
CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430,  
and vhCDR3 of SEQ ID NO:431; and vlCDR1 of SEQ ID NO:434,  
vlCDR2 of SEQ ID NO:435, and vlCDR3 of SEQ ID  
NO:436)~~CHA.7.518.4, CHA.7.518.1, CHA.7.518, CHA.7.524~~  
~~CHA.7.530, CHA.7.538\_1, CHA.7.538\_2, CHA.7.502, CHA.7.503,~~  
~~CHA.7.506, CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514,~~  
~~CHA.7.516, CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522,~~  
~~CHA.7.524, CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530,~~  
~~CHA.7.534, CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2,~~  
~~CHA.7.543, CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547,~~  
~~CHA.7.548, CHA.7.549, CHA.7.550, CHA.7.538.1.2, CPA.7.021,~~  
~~CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009,~~  
~~CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015,~~  
~~CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024,~~  
~~CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047,~~  
~~CPA.7.049, CPA.7.050, and CHA.7.518; and~~

- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.
3. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
- a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and
  - b) a second antigen binding portion comprising:
    - i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
    - ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody;

wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vlCDR1 of SEQ ID NO:1640, vlCDR2 of SEQ ID NO:1641, and vlCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vlCDR1 of SEQ ID NO:1669, vlCDR2 of SEQ ID NO:1670, and vlCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vlCDR1 of SEQ ID NO:1678, vlCDR2 of SEQ ID NO:1679, and vlCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vlCDR1 of SEQ ID NO:1688, vlCDR2 of SEQ ID NO:1689, and vlCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vlCDR1 of SEQ ID NO:1698, vlCDR2 of SEQ ID NO:1699, and vlCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vlCDR1 of SEQ ID NO:1708, vlCDR2 of SEQ ID NO:1709, and vlCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vlCDR1 of SEQ ID NO:1718, vlCDR2 of SEQ ID NO:1719, and vlCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vlCDR1 of SEQ ID NO:1728, vlCDR2 of SEQ ID NO:1729, and vlCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vlCDR1 of SEQ ID NO:1748, vlCDR2 of SEQ ID NO:1749, and vlCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vlCDR1 of SEQ ID NO:1758, vlCDR2 of SEQ ID NO:1759, and vlCDR3 of SEQ ID

NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vlCDR1 of SEQ ID NO:1768, vlCDR2 of SEQ ID NO:1769, and vlCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vlCDR1 of SEQ ID NO:1778, vlCDR2 of SEQ ID NO:1779, and vlCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vlCDR1 of SEQ ID NO:1808, vlCDR2 of SEQ ID NO:1809, and vlCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vlCDR1 of SEQ ID NO:1818, vlCDR2 of SEQ ID NO:1819, and vlCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and vhCDR3 of SEQ ID NO:1825; and vlCDR1 of SEQ ID NO:1828, vlCDR2 of SEQ ID NO:1829, and vlCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vlCDR1 of SEQ ID NO:1838, vlCDR2 of SEQ ID NO:1839, and vlCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vlCDR1 of SEQ ID NO:1848, vlCDR2 of SEQ ID NO:1849, and vlCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vlCDR1 of SEQ ID NO:1858, vlCDR2 of SEQ ID NO:1859, and vlCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vlCDR1 of SEQ ID NO:1868, vlCDR2 of SEQ ID NO:1869, and vlCDR3 of SEQ ID NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vlCDR1 of SEQ ID NO:1878, vlCDR2 of SEQ ID NO:1879, and vlCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ

ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vlCDR1 of SEQ ID NO:1888, vlCDR2 of SEQ ID NO:1889, and vlCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vlCDR1 of SEQ ID NO:1898, vlCDR2 of SEQ ID NO:1899, and vlCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vlCDR1 of SEQ ID NO:1908, vlCDR2 of SEQ ID NO:1909, and vlCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vlCDR1 of SEQ ID NO:1918, vlCDR2 of SEQ ID NO:1919, and vlCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vlCDR1 of SEQ ID NO:1928, vlCDR2 of SEQ ID NO:1929, and vlCDR3 of SEQ ID NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vlCDR1 of SEQ ID NO:1938, vlCDR2 of SEQ ID NO:1939, and vlCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vlCDR1 of SEQ ID NO:1948, vlCDR2 of SEQ ID NO:1949, and vlCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vlCDR1 of SEQ ID NO:1958, vlCDR2 of SEQ ID NO:1959, and vlCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vlCDR1 of SEQ ID NO:1968, vlCDR2 of SEQ ID NO:1969, and vlCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vlCDR1 of SEQ ID NO:1978, vlCDR2 of SEQ ID NO:1979, and vlCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and vhCDR3 of SEQ ID NO:1985; and vlCDR1 of SEQ ID

NO:1988, vlCDR2 of SEQ ID NO:1989, and vlCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vlCDR1 of SEQ ID NO:1998, vlCDR2 of SEQ ID NO:1999, and vlCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID NO:2005; and vlCDR1 of SEQ ID NO:2008, vlCDR2 of SEQ ID NO:2009, and vlCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vlCDR1 of SEQ ID NO:2018, vlCDR2 of SEQ ID NO:2019, and vlCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vlCDR1 of SEQ ID NO:2028, vlCDR2 of SEQ ID NO:2029, and vlCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vlCDR1 of SEQ ID NO:1660, vlCDR2 of SEQ ID NO:1661, and vlCDR3 of SEQ ID NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vlCDR1 of SEQ ID NO:2038, vlCDR2 of SEQ ID NO:2039, and vlCDR3 of SEQ ID NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vlCDR1 of SEQ ID NO:2048, vlCDR2 of SEQ ID NO:2049, and vlCDR3 of SEQ ID NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vlCDR1 of SEQ ID NO:2058, vlCDR2 of SEQ ID NO:2059, and vlCDR3 of SEQ ID NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vlCDR1 of SEQ ID NO:2068, vlCDR2 of SEQ ID NO:2069, and vlCDR3 of SEQ ID NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vlCDR1 of SEQ ID NO:2078, vlCDR2 of SEQ ID NO:2079, and vlCDR3 of SEQ ID

NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vlCDR1 of SEQ ID NO:2088, vlCDR2 of SEQ ID NO:2089, and vlCDR3 of SEQ ID NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vlCDR1 of SEQ ID NO:2098, vlCDR2 of SEQ ID NO:2099, and vlCDR3 of SEQ ID NO:2100)~~CPA.9.086, CHA.9.547.18, CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059, CPA.9.083, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103, CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6, CHA.9.536.7, CHA.9.536.8, CHA.9.560.1, CHA.9.560.3, CHA.9.560.4, CHA.9.560.5, CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1, CHA.9.547.1, CHA.9.547.2, CHA.9.547.3, CHA.9.547.4, CHA.9.547.6, CHA.9.547.7, CHA.9.547.8, CHA.9.547.9, CHA.9.547.13, CHA.9.541.1, CHA.9.541.3, CHA.9.541.4, CHA.9.541.5, CHA.9.541.6, CHA.9.541.7, and CHA.9.541.8.~~

4. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

a) a first antigen binding portion comprising:

- i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
- ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody

wherein the anti-PVRIG antibody is selected from the group consisting of

CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883),

CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915),  
CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947),  
CHA.7.538 1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979),  
CHA.7.538 2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987),  
CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819),  
CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827),  
CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835),  
CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843),  
CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851),  
CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ ID NO:859),  
CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862,

and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865,  
vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867),  
CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of SEQ ID NO:870,  
and vhCDR3 of SEQ ID NO:871; and vlCDR1 of SEQ ID NO:873,  
vlCDR2 of SEQ ID NO:874, and vlCDR3 of SEQ ID NO:875),  
CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886,  
and vhCDR3 of SEQ ID NO:887; and vlCDR1 of SEQ ID NO:889,  
vlCDR2 of SEQ ID NO:890, and vlCDR3 of SEQ ID NO:891),  
CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894,  
and vhCDR3 of SEQ ID NO:895; and vlCDR1 of SEQ ID NO:897,  
vlCDR2 of SEQ ID NO:898, and vlCDR3 of SEQ ID NO:899),  
CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902,  
and vhCDR3 of SEQ ID NO:903; and vlCDR1 of SEQ ID NO:905,  
vlCDR2 of SEQ ID NO:906, and vlCDR3 of SEQ ID NO:907),  
CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918,  
and vhCDR3 of SEQ ID NO:919; and vlCDR1 of SEQ ID NO:921,  
vlCDR2 of SEQ ID NO:922, and vlCDR3 of SEQ ID NO:923),  
CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926,  
and vhCDR3 of SEQ ID NO:927; and vlCDR1 of SEQ ID NO:929,  
vlCDR2 of SEQ ID NO:930, and vlCDR3 of SEQ ID NO:931),  
CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934,  
and vhCDR3 of SEQ ID NO:935; and vlCDR1 of SEQ ID NO:937,  
vlCDR2 of SEQ ID NO:938, and vlCDR3 of SEQ ID NO:939),  
CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950,  
and vhCDR3 of SEQ ID NO:951; and vlCDR1 of SEQ ID NO:953,  
vlCDR2 of SEQ ID NO:954, and vlCDR3 of SEQ ID NO:955),  
CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958,  
and vhCDR3 of SEQ ID NO:959; and vlCDR1 of SEQ ID NO:961,  
vlCDR2 of SEQ ID NO:962, and vlCDR3 of SEQ ID NO:963),  
CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966,  
and vhCDR3 of SEQ ID NO:967; and vlCDR1 of SEQ ID NO:969,

vlCDR2 of SEQ ID NO:970, and vlCDR3 of SEQ ID NO:971),  
CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990,  
and vhCDR3 of SEQ ID NO:991; and vlCDR1 of SEQ ID NO:993,  
vlCDR2 of SEQ ID NO:994, and vlCDR3 of SEQ ID NO:995),  
CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998,  
and vhCDR3 of SEQ ID NO:999; and vlCDR1 of SEQ ID NO:1001,  
vlCDR2 of SEQ ID NO:1002, and vlCDR3 of SEQ ID NO:1003),  
CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID  
NO:1006, and vhCDR3 of SEQ ID NO:1007; and vlCDR1 of SEQ ID  
NO:1009, vlCDR2 of SEQ ID NO:1010, and vlCDR3 of SEQ ID  
NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ  
ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vlCDR1 of SEQ ID  
NO:1017, vlCDR2 of SEQ ID NO:1018, and vlCDR3 of SEQ ID  
NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ  
ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vlCDR1 of SEQ ID  
NO:1025, vlCDR2 of SEQ ID NO:1026, and vlCDR3 of SEQ ID  
NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ  
ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vlCDR1 of SEQ ID  
NO:1033, vlCDR2 of SEQ ID NO:1034, and vlCDR3 of SEQ ID  
NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ  
ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vlCDR1 of SEQ ID  
NO:1041, vlCDR2 of SEQ ID NO:1042, and vlCDR3 of SEQ ID  
NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ  
ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vlCDR1 of SEQ ID  
NO:1049, vlCDR2 of SEQ ID NO:1050, and vlCDR3 of SEQ ID  
NO:1051), CHA.7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of  
SEQ ID NO:1551, and vhCDR3 of SEQ ID NO:1552; and vlCDR1 of  
SEQ ID NO:1555, vlCDR2 of SEQ ID NO:1556, and vlCDR3 of SEQ ID  
NO:1557), CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ ID  
NO:320, and vhCDR3 of SEQ ID NO:321; and vlCDR1 of SEQ ID  
NO:324, vlCDR2 of SEQ ID NO:325, and vlCDR3 of SEQ ID NO:326),

CPA.7.001 (vhCDR1 of SEQ ID NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vlCDR1 of SEQ ID NO:174, vlCDR2 of SEQ ID NO:175, and vlCDR3 of SEQ ID NO:176),  
CPA.7.003 (vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID NO:181; and vlCDR1 of SEQ ID NO:184, vlCDR2 of SEQ ID NO:185, and vlCDR3 of SEQ ID NO:186),  
CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and vhCDR3 of SEQ ID NO:191; and vlCDR1 of SEQ ID NO:194, vlCDR2 of SEQ ID NO:195, and vlCDR3 of SEQ ID NO:196),  
CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vlCDR1 of SEQ ID NO:204, vlCDR2 of SEQ ID NO:205, and vlCDR3 of SEQ ID NO:206),  
CPA.7.008 (vhCDR1 of SEQ ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vlCDR1 of SEQ ID NO:214, vlCDR2 of SEQ ID NO:215, and vlCDR3 of SEQ ID NO:216),  
CPA.7.009 (vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID NO:221; and vlCDR1 of SEQ ID NO:224, vlCDR2 of SEQ ID NO:225, and vlCDR3 of SEQ ID NO:226),  
CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and vhCDR3 of SEQ ID NO:231; and vlCDR1 of SEQ ID NO:234, vlCDR2 of SEQ ID NO:235, and vlCDR3 of SEQ ID NO:236),  
CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vlCDR1 of SEQ ID NO:244, vlCDR2 of SEQ ID NO:245, and vlCDR3 of SEQ ID NO:246),  
CPA.7.012 (vhCDR1 of SEQ ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vlCDR1 of SEQ ID NO:254, vlCDR2 of SEQ ID NO:255, and vlCDR3 of SEQ ID NO:256),  
CPA.7.013 (vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID NO:261; and vlCDR1 of SEQ ID NO:264, vlCDR2 of SEQ ID NO:265, and vlCDR3 of SEQ ID NO:266),  
CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270,

and vhCDR3 of SEQ ID NO:271; and vlCDR1 of SEQ ID NO:274,  
vlCDR2 of SEQ ID NO:275, and vlCDR3 of SEQ ID NO:276),  
CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of SEQ ID NO:280,  
and vhCDR3 of SEQ ID NO:281; and vlCDR1 of SEQ ID NO:284,  
vlCDR2 of SEQ ID NO:285, and vlCDR3 of SEQ ID NO:286),  
CPA.7.017 (vhCDR1 of SEQ ID NO:289, vhCDR2 of SEQ ID NO:290,  
and vhCDR3 of SEQ ID NO:291; and vlCDR1 of SEQ ID NO:294,  
vlCDR2 of SEQ ID NO:295, and vlCDR3 of SEQ ID NO:296),  
CPA.7.018 (vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300,  
and vhCDR3 of SEQ ID NO:301; and vlCDR1 of SEQ ID NO:304,  
vlCDR2 of SEQ ID NO:305, and vlCDR3 of SEQ ID NO:306),  
CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310,  
and vhCDR3 of SEQ ID NO:311; and vlCDR1 of SEQ ID NO:314,  
vlCDR2 of SEQ ID NO:315, and vlCDR3 of SEQ ID NO:316),  
CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of SEQ ID NO:330,  
and vhCDR3 of SEQ ID NO:331; and vlCDR1 of SEQ ID NO:334,  
vlCDR2 of SEQ ID NO:335, and vlCDR3 of SEQ ID NO:336),  
CPA.7.023 (vhCDR1 of SEQ ID NO:339, vhCDR2 of SEQ ID NO:340,  
and vhCDR3 of SEQ ID NO:341; and vlCDR1 of SEQ ID NO:344,  
vlCDR2 of SEQ ID NO:345, and vlCDR3 of SEQ ID NO:346),  
CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350,  
and vhCDR3 of SEQ ID NO:351; and vlCDR1 of SEQ ID NO:354,  
vlCDR2 of SEQ ID NO:355, and vlCDR3 of SEQ ID NO:356),  
CPA.7.033 (vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360,  
and vhCDR3 of SEQ ID NO:361; and vlCDR1 of SEQ ID NO:364,  
vlCDR2 of SEQ ID NO:365, and vlCDR3 of SEQ ID NO:366),  
CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370,  
and vhCDR3 of SEQ ID NO:371; and vlCDR1 of SEQ ID NO:374,  
vlCDR2 of SEQ ID NO:375, and vlCDR3 of SEQ ID NO:376),  
CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380,  
and vhCDR3 of SEQ ID NO:381; and vlCDR1 of SEQ ID NO:384,

vlCDR2 of SEQ ID NO:385, and vlCDR3 of SEQ ID NO:386),  
CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390,  
and vhCDR3 of SEQ ID NO:391; and vlCDR1 of SEQ ID NO:394,  
vlCDR2 of SEQ ID NO:395, and vlCDR3 of SEQ ID NO:396),  
CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400,  
and vhCDR3 of SEQ ID NO:401; and vlCDR1 of SEQ ID NO:404,  
vlCDR2 of SEQ ID NO:405, and vlCDR3 of SEQ ID NO:406),  
CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410,  
and vhCDR3 of SEQ ID NO:411; and vlCDR1 of SEQ ID NO:414,  
vlCDR2 of SEQ ID NO:415, and vlCDR3 of SEQ ID NO:416),  
CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420,  
and vhCDR3 of SEQ ID NO:421; and vlCDR1 of SEQ ID NO:424,  
vlCDR2 of SEQ ID NO:425, and vlCDR3 of SEQ ID NO:426), and  
CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430,  
and vhCDR3 of SEQ ID NO:431; and vlCDR1 of SEQ ID NO:434,  
vlCDR2 of SEQ ID NO:435, and vlCDR3 of SEQ ID  
NO:436)~~CHA.7.518.4, CHA.7.518.1, CHA.7.518, CHA.7.524,~~  
~~CHA.7.530, CHA.7.538\_1, CHA.7.538\_2, CHA.7.502, CHA.7.503,~~  
~~CHA.7.506, CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514,~~  
~~CHA.7.516, CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522,~~  
~~CHA.7.524, CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530,~~  
~~CHA.7.534, CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2,~~  
~~CHA.7.543, CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547,~~  
~~CHA.7.548, CHA.7.549, CHA.7.550, CHA.7.538.1.2, CPA.7.021,~~  
~~CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009,~~  
~~CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015,~~  
~~CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024,~~  
~~CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047,~~  
~~CPA.7.049, and CPA.7.050~~CHA.7.518; and

b) a second antigen binding portion comprising:

- i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
- ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody;

wherein the anti-TIGIT antibody is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vlCDR1 of SEQ ID NO:1640, vlCDR2 of SEQ ID NO:1641, and vlCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vlCDR1 of SEQ ID NO:1669, vlCDR2 of SEQ ID NO:1670, and vlCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vlCDR1 of SEQ ID NO:1678, vlCDR2 of SEQ ID NO:1679, and vlCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vlCDR1 of SEQ ID NO:1688, vlCDR2 of SEQ ID NO:1689, and vlCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vlCDR1 of SEQ ID NO:1698, vlCDR2 of SEQ ID NO:1699, and vlCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vlCDR1 of SEQ ID NO:1708, vlCDR2 of SEQ ID NO:1709, and vlCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vlCDR1 of SEQ ID NO:1718, vlCDR2 of SEQ ID NO:1719, and vlCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vlCDR1 of SEQ ID NO:1728, vlCDR2 of SEQ ID NO:1729, and vlCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vlCDR1 of SEQ ID

NO:1748, vlCDR2 of SEQ ID NO:1749, and vlCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vlCDR1 of SEQ ID NO:1758, vlCDR2 of SEQ ID NO:1759, and vlCDR3 of SEQ ID NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vlCDR1 of SEQ ID NO:1768, vlCDR2 of SEQ ID NO:1769, and vlCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vlCDR1 of SEQ ID NO:1778, vlCDR2 of SEQ ID NO:1779, and vlCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vlCDR1 of SEQ ID NO:1808, vlCDR2 of SEQ ID NO:1809, and vlCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vlCDR1 of SEQ ID NO:1818, vlCDR2 of SEQ ID NO:1819, and vlCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and vhCDR3 of SEQ ID NO:1825; and vlCDR1 of SEQ ID NO:1828, vlCDR2 of SEQ ID NO:1829, and vlCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vlCDR1 of SEQ ID NO:1838, vlCDR2 of SEQ ID NO:1839, and vlCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vlCDR1 of SEQ ID NO:1848, vlCDR2 of SEQ ID NO:1849, and vlCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vlCDR1 of SEQ ID NO:1858, vlCDR2 of SEQ ID NO:1859, and vlCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vlCDR1 of SEQ ID NO:1868, vlCDR2 of SEQ ID NO:1869, and vlCDR3 of SEQ ID

NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vlCDR1 of SEQ ID NO:1878, vlCDR2 of SEQ ID NO:1879, and vlCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vlCDR1 of SEQ ID NO:1888, vlCDR2 of SEQ ID NO:1889, and vlCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vlCDR1 of SEQ ID NO:1898, vlCDR2 of SEQ ID NO:1899, and vlCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vlCDR1 of SEQ ID NO:1908, vlCDR2 of SEQ ID NO:1909, and vlCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vlCDR1 of SEQ ID NO:1918, vlCDR2 of SEQ ID NO:1919, and vlCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vlCDR1 of SEQ ID NO:1928, vlCDR2 of SEQ ID NO:1929, and vlCDR3 of SEQ ID NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vlCDR1 of SEQ ID NO:1938, vlCDR2 of SEQ ID NO:1939, and vlCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vlCDR1 of SEQ ID NO:1948, vlCDR2 of SEQ ID NO:1949, and vlCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vlCDR1 of SEQ ID NO:1958, vlCDR2 of SEQ ID NO:1959, and vlCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vlCDR1 of SEQ ID NO:1968, vlCDR2 of SEQ ID NO:1969, and vlCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ

ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vlCDR1 of SEQ ID NO:1978, vlCDR2 of SEQ ID NO:1979, and vlCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and vhCDR3 of SEQ ID NO:1985; and vlCDR1 of SEQ ID NO:1988, vlCDR2 of SEQ ID NO:1989, and vlCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vlCDR1 of SEQ ID NO:1998, vlCDR2 of SEQ ID NO:1999, and vlCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID NO:2005; and vlCDR1 of SEQ ID NO:2008, vlCDR2 of SEQ ID NO:2009, and vlCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vlCDR1 of SEQ ID NO:2018, vlCDR2 of SEQ ID NO:2019, and vlCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vlCDR1 of SEQ ID NO:2028, vlCDR2 of SEQ ID NO:2029, and vlCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vlCDR1 of SEQ ID NO:1660, vlCDR2 of SEQ ID NO:1661, and vlCDR3 of SEQ ID NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vlCDR1 of SEQ ID NO:2038, vlCDR2 of SEQ ID NO:2039, and vlCDR3 of SEQ ID NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vlCDR1 of SEQ ID NO:2048, vlCDR2 of SEQ ID NO:2049, and vlCDR3 of SEQ ID NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vlCDR1 of SEQ ID NO:2058, vlCDR2 of SEQ ID NO:2059, and vlCDR3 of SEQ ID NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vlCDR1 of SEQ ID

NO:2068, vlCDR2 of SEQ ID NO:2069, and vlCDR3 of SEQ ID NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vlCDR1 of SEQ ID NO:2078, vlCDR2 of SEQ ID NO:2079, and vlCDR3 of SEQ ID NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vlCDR1 of SEQ ID NO:2088, vlCDR2 of SEQ ID NO:2089, and vlCDR3 of SEQ ID NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vlCDR1 of SEQ ID NO:2098, vlCDR2 of SEQ ID NO:2099, and vlCDR3 of SEQ ID NO:2100)~~CPA.9.086, CHA.9.547.18, CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059, CPA.9.083, CPA.9.086, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103, CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6, CHA.9.536.7, CHA.9.536.8, CHA.9.560.1, CHA.9.560.3, CHA.9.560.4, CHA.9.560.5, CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1, CHA.9.547.1, CHA.9.547.2, CHA.9.547.3, CHA.9.547.4, CHA.9.547.6, CHA.9.547.7, CHA.9.547.8, CHA.9.547.9, CHA.9.547.13, CHA.9.541.1, CHA.9.541.3, CHA.9.541.4, CHA.9.541.5, CHA.9.541.6, CHA.9.541.7, and CHA.9.541.8.~~

5. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 4, wherein first antigen binding portion comprises:
  - i. a first heavy chain comprising VH-CH1-hinge-CH2-CH3; and
  - ii. a first light chain comprising VL-CL, wherein the CL is the constant domain of either a kappa or lambda antibody.
6. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 5, wherein the first heavy chain CH3 comprises ~~the~~ amino acid substitutions S354C, E356D, M358L, and T366W.
7. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 5, wherein the CL is kappa.
8. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 4, wherein the second antigen binding portion comprises:

- i. a second heavy chain comprising ~~H~~EVH-CL-hinge-CH2-CH3, wherein the CL is either kappa or lambda; and
  - ii. a second light chain comprising VL-CH1.
- 9. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 8, wherein the second heavy chain CH3 comprises ~~the~~-amino acid substitutions Y349C, E356D, M358L, T366S, L368A, and Y407V.
- 10. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 8, wherein the CL is lambda.
- 11. The anti-PVRIG/anti-TIGIT bispecific antibody of claim 8, wherein the CL is kappa.
- 12. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
  - a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and
  - b) a second anti-TIGIT antigen binding portion comprising:
    - i. a second heavy chain variable region comprising CPA.9.086 VH  
(EVQLVETGGGLIQGRSLRLSCAASGFTFSSYAMHWVRQAPGKG  
LEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMNSLRAE  
DTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS; SEQ ID  
NO:1634); and
    - ii. a second light chain variable region comprising CPA.9.086 VL  
(QSALTQPRSASGNPGQRVTISCSGSSSNMGRRPVNWYQQIPGTAP  
KLLIYSQNQRPSGVPDRFSGS QSGTSASLTISGLQSEDEAEYFCAV  
WDDIGRVLQLGGGTQLAVL; SEQ ID NO:1639).
- 13. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
  - c) a first antigen binding portion comprising an anti-PVRIG antigen binding domain; and
  - d) a second anti-TIGIT antigen binding portion comprising:
    - i. a second heavy chain variable region comprising CPA.9.547.18  
VH  
(EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQA  
PGKGLEWVATISGGSGKQYYADSVKGRFTISRDN SKNTLY

LQMNSLRAEDTAVYYCAKWLLSY~~Y~~AMDYWGQGLVTVS  
S; SEQ ID NO:1664); and

- ii. a second light chain variable region comprising CPA.9.547.18 VL  
(DIQMTQSPSSLSASVGDRITITCRASQSM~~AI~~WLSWYQQKPG  
KAPKLLIYK~~AS~~KSHTGVPSRFSGSGSGTDFTLTISLQPEDFA  
TYYCQ~~Q~~QGSYPYTFGQGTKLEIK; SEQ ID NO:1668).

14. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.1 VH  
(QVQLVQSGAEVKKPGASVKV~~S~~CKASGYTFTDYNINWVRQAPGQ  
GLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRS  
EDTAVYYCAREDKTARNAMDYWGQGLVTVSS; SEQ ID  
NO:1539); and
  - ii. a first light chain variable region comprising CHA.7.518.1 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHFW  
GTPYTFGQGTKLEIK; SEQ ID NO:1544); and
- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.

15. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.4 VH  
(QVQLVQSGAEVKKPGASVKV~~S~~CKASGYTFTDYNINWVRQAPGQ  
GLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRS  
EDTAVYYCAREDKTARNAMDYWGQGLVTVSS; SEQ ID  
NO:3179); and
  - ii. a first light chain variable region comprising CHA.7.518.4 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHFW  
GTPYTFGQGTKLEIK; SEQ ID NO:3180); and

- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain.
16. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
    - i. a first heavy chain variable region comprising CHA.7.518.1 VH  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQ  
GLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRS  
EDTAVYYCAREDKTARNAMDYWGQGTLLTVSS; SEQ ID  
NO:1539); and
    - ii. a first light chain variable region comprising CHA.7.518.1  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHFV  
GTPYTFGQGTKLEIK; SEQ ID NO:1544); and
  - b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising
    - i. a first heavy chain variable region comprising CPA.9.086 VH  
(EVQLVETGGGLIQGRSLRLSCAASGFTFSSYAMHWVRQAPGKG  
LEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMNSLRAE  
DTAVYYCARDPLPLHYYGMDVWGQGTTLTVSS; SEQ ID  
NO:1634); and
    - ii. a first light chain variable region comprising CPA.9.086 VL  
(QSALTQPRASGNPGQRVTISCSGSSSNMGRRPVNWYQQIPGTAP  
KLLIYSQNQRPSGVPDRFSGSQSGTSASLTISGLQSEDEAEYFCAV  
WDDIGRVLQLGGGTQLAVL; SEQ ID NO: 1639).
17. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
    - i. a first heavy chain variable region comprising CHA.7.518.4 VH  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQ  
GLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRS

EDTAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ ID NO:3179); and

- ii. a first light chain variable region comprising CHA.7.518.4 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHFW  
GTPYTFGQGGTKLEIK; SEQ ID NO:3180); and

- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:

- i. a first heavy chain variable region comprising CPA.9.086 VH  
(EVQLVETGGGLIQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKG  
LEWVAVISYAGEVKYYADSVKGRFTISRDN SKNTLYLQMNSLRAE  
DTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS; SEQ ID NO:1634); and
- ii. a first light chain variable region comprising CPA.9.086 VL  
(QSALTQPRASGNPGQRTVITSCGSSSNMGRRPVNWYQQIPGTAP  
KLLIYSQNQRPSGVPDRFSGSQTSTASLTISGLQSEDEAEYFCAV  
WDDIGRVLQLGGGTQLAVL; SEQ ID NO:1639).

18. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:

- i. a first heavy chain variable region comprising CHA.7.518.1  
(QVQLVQSGAEVKKPGASVKVSCASGYTFDYNINWVRQAPGQ  
GLEWMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRS  
EDTAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ ID NO:  
1539); and
- ii. a first light chain variable region comprising CHA.7.518.1 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYSNLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHFW  
GTPYTFGQGGTKLEIK; SEQ ID NO: 1544); and

- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:

- i. a first heavy chain variable region comprising CHA.9.547.18 HC  
(EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGKGL  
EWVATISGGSKGQYYADSVKGRFTISRDN SKNTLYLQMNSLRAED  
TAVYYCAKWLLSYYAMDYWGQGTLVTVSS; SEQ ID NO: 1664);  
and
- ii. a first light chain variable region comprising CHA.9.547.18 VL  
(DIQMTQSPSSLSASVGDRITITCRASQSMAIWLSWYQQKPGKAPK  
LLIYKASKSHTGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGQ  
SYPYTFGQGGTKLEIK; SEQ ID NO: 1668).

19. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.7.518.4 VH  
(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQ  
GLEWMGYIYPYIGSGGYAQKFQGRVTMTRDTSTSTVYMELSSLRS  
EDTAVYYCAREDKTARNAMDYWGQGTLVTVSS; SEQ ID  
NO:3179); and
  - ii. a first light chain variable region comprising CHA.7.518.4 VL  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPK  
LLIYEATNLAEGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQHF  
W GTPYTFGQGGTKLEIK; SEQ ID NO:3180); and
- b) a second antigen binding portion comprising an anti-TIGIT binding domain comprising:
  - i. a first heavy chain variable region comprising CHA.9.547.18 HC  
(EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGKGL  
EWVATISGGSKGQYYADSVKGRFTISRDN SKNTLYLQMNSLRAED  
TAVYYCAKWLLSYYAMDYWGQGTLVTVSS (SEQ ID NO: 1664);  
and
  - ii. a first light chain variable region comprising CHA.9.547.18 VL  
(DIQMTQSPSSLSASVGDRITITCRASQSMAIWLSWYQQKPGKAPK

LLIYKASKSHTGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGQ  
SYPYTFGQGKLEIK; SEQ ID NO: 1668).

20. An anti-PVRIG/anti-TIGIT bispecific antibody according to any one of claims 1-19 and 37-38 wherein said anti-PVRIG/anti-TIGIT bispecific antibody is a humanized antibody.
21. A composition comprising an anti-PVRIG/anti-TIGIT bispecific antibody according to any one of claims 1 to 20.
22. A nucleic acid composition comprising:
- a) a first nucleic acid encoding a first heavy chain or heavy chain variable domain according to any one of claims 1 to 20;
  - b) a second nucleic acid encoding a first light chain or light chain variable domain according to any one of claims 1 to 20;
  - c) a third nucleic acid encoding a second heavy chain or heavy chain variable domain according to any one of claims 1 to 20; and
  - d) a fourth nucleic acid encoding a second light chain or light chain variable domain according to any one of claims 1 to 20.
23. An expression vector composition comprising:
- a) a first expression vector comprising the first nucleic acid of claim 22;
  - b) a second expression vector comprising the second nucleic acid of claim 22;
  - c) a third expression vector comprising the third nucleic acid of claim 22; and
  - d) a fourth expression vector comprising the fourth nucleic acid of claim 22.
24. An expression vector composition comprising:
- a) a first expression vector comprising the first and second nucleic acids of claim 22; and
  - b) a second expression vector comprising the third and fourth nucleic acids of claim 22.
25. A host cell comprising the expression vector composition of claim 23 or claim 24.
26. A method of making an anti-PVRIG/anti-TIGIT bispecific antibody comprising:
- a) culturing the host cell of claim 25 under conditions wherein the antibody is expressed; and

- b) recovering the antibody.
27. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by activating T cells of ~~a~~-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated.
28. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of ~~a~~-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated.
29. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by activating NK cells of ~~a~~-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the NK cells of the patient are to be activated.
30. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of ~~a~~the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are to be activated.
31. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by activating Th1 cells of ~~a~~-the cancer patient, wherein said bispecific antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient are to be activated.
32. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in ~~a~~-the cancer patient, wherein said bispecific antibody is to be administered to the patient.
33. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$

production and/or pro-inflammatory cytokine secretion in thea cancer patient, wherein said bispecific antibody is to be administered to the patient.

34. Use of the anti-PVRIG/anti-TIGIT bispecific antibody of any one of claims 1 to 20 in the manufacture of a medicament for treating cancer in a patient, wherein said bispecific antibody is to be administered to the patient.
35. The use of claim 34, wherein the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).
36. The use of claim 35, wherein the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).
37. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:
  - a) a first antigen binding portion comprising an anti-PVRIG antigen binding portion comprising:
    - i. a first heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-PVRIG antibody; and
    - ii. a first light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-PVRIG antibody;wherein the anti-PVRIG antigen binding portion is selected from the group consisting of CHA.7.518.4 (vhCDR1 of SEQ ID NO:1053, vhCDR2 of SEQ ID NO:1054, and vhCDR3 of SEQ ID NO:1055; and

vlCDR1 of SEQ ID NO:1057, vlCDR2 of SEQ ID NO:1058, and vlCDR3 of SEQ ID NO:1059), CHA.7.518.1 (vhCDR1 of SEQ ID NO:1540, vhCDR2 of SEQ ID NO:1541, and vhCDR3 of SEQ ID NO:1542; and vlCDR1 of SEQ ID NO:1545, vlCDR2 of SEQ ID NO:1546, and vlCDR3 of SEQ ID NO:1547), CHA.7.518 (vhCDR1 of SEQ ID NO:877, vhCDR2 of SEQ ID NO:878, and vhCDR3 of SEQ ID NO:879; and vlCDR1 of SEQ ID NO:881, vlCDR2 of SEQ ID NO:882, and vlCDR3 of SEQ ID NO:883), CHA.7.524 (vhCDR1 of SEQ ID NO:909, vhCDR2 of SEQ ID NO:910, and vhCDR3 of SEQ ID NO:911; and vlCDR1 of SEQ ID NO:913, vlCDR2 of SEQ ID NO:914, and vlCDR3 of SEQ ID NO:915), CHA.7.530 (vhCDR1 of SEQ ID NO:941, vhCDR2 of SEQ ID NO:942, and vhCDR3 of SEQ ID NO:943; and vlCDR1 of SEQ ID NO:945, vlCDR2 of SEQ ID NO:946, and vlCDR3 of SEQ ID NO:947), CHA.7.538\_1 (vhCDR1 of SEQ ID NO:973, vhCDR2 of SEQ ID NO:974, and vhCDR3 of SEQ ID NO:975; and vlCDR1 of SEQ ID NO:977, vlCDR2 of SEQ ID NO:978, and vlCDR3 of SEQ ID NO:979), CHA.7.538\_2 (vhCDR1 of SEQ ID NO:981, vhCDR2 of SEQ ID NO:982, and vhCDR3 of SEQ ID NO:983; and vlCDR1 of SEQ ID NO:985, vlCDR2 of SEQ ID NO:986, and vlCDR3 of SEQ ID NO:987), CHA.7.502 (vhCDR1 of SEQ ID NO:813, vhCDR2 of SEQ ID NO:814, and vhCDR3 of SEQ ID NO:815; and vlCDR1 of SEQ ID NO:817, vlCDR2 of SEQ ID NO:818, and vlCDR3 of SEQ ID NO:819), CHA.7.503 (vhCDR1 of SEQ ID NO:821, vhCDR2 of SEQ ID NO:822, and vhCDR3 of SEQ ID NO:823; and vlCDR1 of SEQ ID NO:825, vlCDR2 of SEQ ID NO:826, and vlCDR3 of SEQ ID NO:827), CHA.7.506 (vhCDR1 of SEQ ID NO:829, vhCDR2 of SEQ ID NO:830, and vhCDR3 of SEQ ID NO:831; and vlCDR1 of SEQ ID NO:833, vlCDR2 of SEQ ID NO:834, and vlCDR3 of SEQ ID NO:835), CHA.7.508 (vhCDR1 of SEQ ID NO:837, vhCDR2 of SEQ ID NO:838, and vhCDR3 of SEQ ID NO:839; and vlCDR1 of SEQ ID NO:841, vlCDR2 of SEQ ID NO:842, and vlCDR3 of SEQ ID NO:843),

CHA.7.510 (vhCDR1 of SEQ ID NO:845, vhCDR2 of SEQ ID NO:846, and vhCDR3 of SEQ ID NO:847; and vlCDR1 of SEQ ID NO:849, vlCDR2 of SEQ ID NO:850, and vlCDR3 of SEQ ID NO:851),  
CHA.7.512 (vhCDR1 of SEQ ID NO:853, vhCDR2 of SEQ ID NO:854, and vhCDR3 of SEQ ID NO:855; and vlCDR1 of SEQ ID NO:857, vlCDR2 of SEQ ID NO:858, and vlCDR3 of SEQ ID NO:859),  
CHA.7.514 (vhCDR1 of SEQ ID NO:861, vhCDR2 of SEQ ID NO:862, and vhCDR3 of SEQ ID NO:863; and vlCDR1 of SEQ ID NO:865, vlCDR2 of SEQ ID NO:866, and vlCDR3 of SEQ ID NO:867),  
CHA.7.516 (vhCDR1 of SEQ ID NO:869, vhCDR2 of SEQ ID NO:870, and vhCDR3 of SEQ ID NO:871; and vlCDR1 of SEQ ID NO:873, vlCDR2 of SEQ ID NO:874, and vlCDR3 of SEQ ID NO:875),  
CHA.7.520.1 (vhCDR1 of SEQ ID NO:885, vhCDR2 of SEQ ID NO:886, and vhCDR3 of SEQ ID NO:887; and vlCDR1 of SEQ ID NO:889, vlCDR2 of SEQ ID NO:890, and vlCDR3 of SEQ ID NO:891),  
CHA.7.520.2 (vhCDR1 of SEQ ID NO:893, vhCDR2 of SEQ ID NO:894, and vhCDR3 of SEQ ID NO:895; and vlCDR1 of SEQ ID NO:897, vlCDR2 of SEQ ID NO:898, and vlCDR3 of SEQ ID NO:899),  
CHA.7.522 (vhCDR1 of SEQ ID NO:901, vhCDR2 of SEQ ID NO:902, and vhCDR3 of SEQ ID NO:903; and vlCDR1 of SEQ ID NO:905, vlCDR2 of SEQ ID NO:906, and vlCDR3 of SEQ ID NO:907),  
CHA.7.526 (vhCDR1 of SEQ ID NO:917, vhCDR2 of SEQ ID NO:918, and vhCDR3 of SEQ ID NO:919; and vlCDR1 of SEQ ID NO:921, vlCDR2 of SEQ ID NO:922, and vlCDR3 of SEQ ID NO:923),  
CHA.7.527 (vhCDR1 of SEQ ID NO:925, vhCDR2 of SEQ ID NO:926, and vhCDR3 of SEQ ID NO:927; and vlCDR1 of SEQ ID NO:929, vlCDR2 of SEQ ID NO:930, and vlCDR3 of SEQ ID NO:931),  
CHA.7.528 (vhCDR1 of SEQ ID NO:933, vhCDR2 of SEQ ID NO:934, and vhCDR3 of SEQ ID NO:935; and vlCDR1 of SEQ ID NO:937, vlCDR2 of SEQ ID NO:938, and vlCDR3 of SEQ ID NO:939),  
CHA.7.534 (vhCDR1 of SEQ ID NO:949, vhCDR2 of SEQ ID NO:950,

and vhCDR3 of SEQ ID NO:951; and vlCDR1 of SEQ ID NO:953, vlCDR2 of SEQ ID NO:954, and vlCDR3 of SEQ ID NO:955),  
CHA.7.535 (vhCDR1 of SEQ ID NO:957, vhCDR2 of SEQ ID NO:958,  
and vhCDR3 of SEQ ID NO:959; and vlCDR1 of SEQ ID NO:961,  
vlCDR2 of SEQ ID NO:962, and vlCDR3 of SEQ ID NO:963),  
CHA.7.537 (vhCDR1 of SEQ ID NO:965, vhCDR2 of SEQ ID NO:966,  
and vhCDR3 of SEQ ID NO:967; and vlCDR1 of SEQ ID NO:969,  
vlCDR2 of SEQ ID NO:970, and vlCDR3 of SEQ ID NO:971),  
CHA.7.543 (vhCDR1 of SEQ ID NO:989, vhCDR2 of SEQ ID NO:990,  
and vhCDR3 of SEQ ID NO:991; and vlCDR1 of SEQ ID NO:993,  
vlCDR2 of SEQ ID NO:994, and vlCDR3 of SEQ ID NO:995),  
CHA.7.544 (vhCDR1 of SEQ ID NO:997, vhCDR2 of SEQ ID NO:998,  
and vhCDR3 of SEQ ID NO:999; and vlCDR1 of SEQ ID NO:1001,  
vlCDR2 of SEQ ID NO:1002, and vlCDR3 of SEQ ID NO:1003),  
CHA.7.545 (vhCDR1 of SEQ ID NO:1005, vhCDR2 of SEQ ID  
NO:1006, and vhCDR3 of SEQ ID NO:1007; and vlCDR1 of SEQ ID  
NO:1009, vlCDR2 of SEQ ID NO:1010, and vlCDR3 of SEQ ID  
NO:1011), CHA.7.546 (vhCDR1 of SEQ ID NO:1013, vhCDR2 of SEQ  
ID NO:1014, and vhCDR3 of SEQ ID NO:1015; and vlCDR1 of SEQ ID  
NO:1017, vlCDR2 of SEQ ID NO:1018, and vlCDR3 of SEQ ID  
NO:1019), CHA.7.547 (vhCDR1 of SEQ ID NO:1021, vhCDR2 of SEQ  
ID NO:1022, and vhCDR3 of SEQ ID NO:1023; and vlCDR1 of SEQ ID  
NO:1025, vlCDR2 of SEQ ID NO:1026, and vlCDR3 of SEQ ID  
NO:1027), CHA.7.548 (vhCDR1 of SEQ ID NO:1029, vhCDR2 of SEQ  
ID NO:1030, and vhCDR3 of SEQ ID NO:1031; and vlCDR1 of SEQ ID  
NO:1033, vlCDR2 of SEQ ID NO:1034, and vlCDR3 of SEQ ID  
NO:1035), CHA.7.549 (vhCDR1 of SEQ ID NO:1037, vhCDR2 of SEQ  
ID NO:1038, and vhCDR3 of SEQ ID NO:1039; and vlCDR1 of SEQ ID  
NO:1041, vlCDR2 of SEQ ID NO:1042, and vlCDR3 of SEQ ID  
NO:1043), CHA.7.550 (vhCDR1 of SEQ ID NO:1045, vhCDR2 of SEQ  
ID NO:1046, and vhCDR3 of SEQ ID NO:1047; and vlCDR1 of SEQ ID

NO:1049, vlCDR2 of SEQ ID NO:1050, and vlCDR3 of SEQ ID NO:1051), CHA7.538.1.2 (vhCDR1 of SEQ ID NO:1550, vhCDR2 of SEQ ID NO:1551, and vhCDR3 of SEQ ID NO:1552; and vlCDR1 of SEQ ID NO:1555, vlCDR2 of SEQ ID NO:1556, and vlCDR3 of SEQ ID NO:1557), CPA.7.021 (vhCDR1 of SEQ ID NO:319, vhCDR2 of SEQ ID NO:320, and vhCDR3 of SEQ ID NO:321; and vlCDR1 of SEQ ID NO:324, vlCDR2 of SEQ ID NO:325, and vlCDR3 of SEQ ID NO:326), CPA.7.001 (vhCDR1 of SEQ ID NO:169, vhCDR2 of SEQ ID NO:170, and vhCDR3 of SEQ ID NO:171; and vlCDR1 of SEQ ID NO:174, vlCDR2 of SEQ ID NO:175, and vlCDR3 of SEQ ID NO:176), CPA.7.003 (vhCDR1 of SEQ ID NO:179, vhCDR2 of SEQ ID NO:180, and vhCDR3 of SEQ ID NO:181; and vlCDR1 of SEQ ID NO:184, vlCDR2 of SEQ ID NO:185, and vlCDR3 of SEQ ID NO:186), CPA.7.004 (vhCDR1 of SEQ ID NO:189, vhCDR2 of SEQ ID NO:190, and vhCDR3 of SEQ ID NO:191; and vlCDR1 of SEQ ID NO:194, vlCDR2 of SEQ ID NO:195, and vlCDR3 of SEQ ID NO:196), CPA.7.006 (vhCDR1 of SEQ ID NO:199, vhCDR2 of SEQ ID NO:200, and vhCDR3 of SEQ ID NO:201; and vlCDR1 of SEQ ID NO:204, vlCDR2 of SEQ ID NO:205, and vlCDR3 of SEQ ID NO:206), CPA.7.008 (vhCDR1 of SEQ ID NO:209, vhCDR2 of SEQ ID NO:210, and vhCDR3 of SEQ ID NO:210; and vlCDR1 of SEQ ID NO:214, vlCDR2 of SEQ ID NO:215, and vlCDR3 of SEQ ID NO:216), CPA.7.009 (vhCDR1 of SEQ ID NO:219, vhCDR2 of SEQ ID NO:220, and vhCDR3 of SEQ ID NO:221; and vlCDR1 of SEQ ID NO:224, vlCDR2 of SEQ ID NO:225, and vlCDR3 of SEQ ID NO:226), CPA.7.010 (vhCDR1 of SEQ ID NO:229, vhCDR2 of SEQ ID NO:230, and vhCDR3 of SEQ ID NO:231; and vlCDR1 of SEQ ID NO:234, vlCDR2 of SEQ ID NO:235, and vlCDR3 of SEQ ID NO:236), CPA.7.011 (vhCDR1 of SEQ ID NO:239, vhCDR2 of SEQ ID NO:240, and vhCDR3 of SEQ ID NO:241; and vlCDR1 of SEQ ID NO:244, vlCDR2 of SEQ ID NO:245, and vlCDR3 of SEQ ID NO:246),

CPA.7.012 (vhCDR1 of SEQ ID NO:249, vhCDR2 of SEQ ID NO:250, and vhCDR3 of SEQ ID NO:251; and vlCDR1 of SEQ ID NO:254, vlCDR2 of SEQ ID NO:255, and vlCDR3 of SEQ ID NO:256),  
CPA.7.013 (vhCDR1 of SEQ ID NO:259, vhCDR2 of SEQ ID NO:260, and vhCDR3 of SEQ ID NO:261; and vlCDR1 of SEQ ID NO:264, vlCDR2 of SEQ ID NO:265, and vlCDR3 of SEQ ID NO:266),  
CPA.7.014 (vhCDR1 of SEQ ID NO:269, vhCDR2 of SEQ ID NO:270, and vhCDR3 of SEQ ID NO:271; and vlCDR1 of SEQ ID NO:274, vlCDR2 of SEQ ID NO:275, and vlCDR3 of SEQ ID NO:276),  
CPA.7.015 (vhCDR1 of SEQ ID NO:279, vhCDR2 of SEQ ID NO:280, and vhCDR3 of SEQ ID NO:281; and vlCDR1 of SEQ ID NO:284, vlCDR2 of SEQ ID NO:285, and vlCDR3 of SEQ ID NO:286),  
CPA.7.017 (vhCDR1 of SEQ ID NO:289, vhCDR2 of SEQ ID NO:290, and vhCDR3 of SEQ ID NO:291; and vlCDR1 of SEQ ID NO:294, vlCDR2 of SEQ ID NO:295, and vlCDR3 of SEQ ID NO:296),  
CPA.7.018 (vhCDR1 of SEQ ID NO:299, vhCDR2 of SEQ ID NO:300, and vhCDR3 of SEQ ID NO:301; and vlCDR1 of SEQ ID NO:304, vlCDR2 of SEQ ID NO:305, and vlCDR3 of SEQ ID NO:306),  
CPA.7.019 (vhCDR1 of SEQ ID NO:309, vhCDR2 of SEQ ID NO:310, and vhCDR3 of SEQ ID NO:311; and vlCDR1 of SEQ ID NO:314, vlCDR2 of SEQ ID NO:315, and vlCDR3 of SEQ ID NO:316),  
CPA.7.022 (vhCDR1 of SEQ ID NO:329, vhCDR2 of SEQ ID NO:330, and vhCDR3 of SEQ ID NO:331; and vlCDR1 of SEQ ID NO:334, vlCDR2 of SEQ ID NO:335, and vlCDR3 of SEQ ID NO:336),  
CPA.7.023 (vhCDR1 of SEQ ID NO:339, vhCDR2 of SEQ ID NO:340, and vhCDR3 of SEQ ID NO:341; and vlCDR1 of SEQ ID NO:344, vlCDR2 of SEQ ID NO:345, and vlCDR3 of SEQ ID NO:346),  
CPA.7.024 (vhCDR1 of SEQ ID NO:349, vhCDR2 of SEQ ID NO:350, and vhCDR3 of SEQ ID NO:351; and vlCDR1 of SEQ ID NO:354, vlCDR2 of SEQ ID NO:355, and vlCDR3 of SEQ ID NO:356),  
CPA.7.033 (vhCDR1 of SEQ ID NO:359, vhCDR2 of SEQ ID NO:360,

and vhCDR3 of SEQ ID NO:361; and vlCDR1 of SEQ ID NO:364,  
vlCDR2 of SEQ ID NO:365, and vlCDR3 of SEQ ID NO:366),  
CPA.7.034 (vhCDR1 of SEQ ID NO:369, vhCDR2 of SEQ ID NO:370,  
and vhCDR3 of SEQ ID NO:371; and vlCDR1 of SEQ ID NO:374,  
vlCDR2 of SEQ ID NO:375, and vlCDR3 of SEQ ID NO:376),  
CPA.7.036 (vhCDR1 of SEQ ID NO:379, vhCDR2 of SEQ ID NO:380,  
and vhCDR3 of SEQ ID NO:381; and vlCDR1 of SEQ ID NO:384,  
vlCDR2 of SEQ ID NO:385, and vlCDR3 of SEQ ID NO:386),  
CPA.7.040 (vhCDR1 of SEQ ID NO:389, vhCDR2 of SEQ ID NO:390,  
and vhCDR3 of SEQ ID NO:391; and vlCDR1 of SEQ ID NO:394,  
vlCDR2 of SEQ ID NO:395, and vlCDR3 of SEQ ID NO:396),  
CPA.7.046 (vhCDR1 of SEQ ID NO:399, vhCDR2 of SEQ ID NO:400,  
and vhCDR3 of SEQ ID NO:401; and vlCDR1 of SEQ ID NO:404,  
vlCDR2 of SEQ ID NO:405, and vlCDR3 of SEQ ID NO:406),  
CPA.7.047 (vhCDR1 of SEQ ID NO:409, vhCDR2 of SEQ ID NO:410,  
and vhCDR3 of SEQ ID NO:411; and vlCDR1 of SEQ ID NO:414,  
vlCDR2 of SEQ ID NO:415, and vlCDR3 of SEQ ID NO:416),  
CPA.7.049 (vhCDR1 of SEQ ID NO:419, vhCDR2 of SEQ ID NO:420,  
and vhCDR3 of SEQ ID NO:421; and vlCDR1 of SEQ ID NO:424,  
vlCDR2 of SEQ ID NO:425, and vlCDR3 of SEQ ID NO:426), and  
CPA.7.050 (vhCDR1 of SEQ ID NO:429, vhCDR2 of SEQ ID NO:430,  
and vhCDR3 of SEQ ID NO:431; and vlCDR1 of SEQ ID NO:434,  
vlCDR2 of SEQ ID NO:435, and vlCDR3 of SEQ ID NO:436)CPA.7.021,  
~~CPA.7.001, CPA.7.003, CPA.7.004, CPA.7.006, CPA.7.008, CPA.7.009,~~  
~~CPA.7.010, CPA.7.011, CPA.7.012, CPA.7.013, CPA.7.014, CPA.7.015,~~  
~~CPA.7.017, CPA.7.018, CPA.7.019, CPA.7.022, CPA.7.023, CPA.7.024,~~  
~~CPA.7.033, CPA.7.034, CPA.7.036, CPA.7.040, CPA.7.046, CPA.7.047,~~  
~~CPA.7.049, CPA.7.050, CHA.7.502, CHA.7.503, CHA.7.506,~~  
~~CHA.7.508, CHA.7.510, CHA.7.512, CHA.7.514, CHA.7.516,~~  
~~CHA.7.518, CHA.7.520.1, CHA.7.520.2, CHA.7.522, CHA.7.524,~~  
~~CHA.7.526, CHA.7.527, CHA.7.528, CHA.7.530, CHA.7.534,~~

~~CHA.7.535, CHA.7.537, CHA.7.538.1, CHA.7.538.2, CHA.7.543,  
CHA.7.544, CHA.7.545, CHA.7.546, CHA.7.547, CHA.7.548,  
CHA.7.549, CHA.7.550, CHA.7.518.1; CHA.7.538.1.2 and CHA.7.518.4;~~  
and

- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain, wherein the anti-TIGIT antigen binding domain is from an antibody as provided in Figures 24 and 41, and in particular Figure 24A-24EE.

38. An anti-PVRIG/anti-TIGIT bispecific antibody comprising:

- a) a first antigen binding portion comprising an anti-PVRIG antigen binding domain wherein the anti-PVRIG antigen binding domain is from an antibody as provided in Figure 35; and
- b) a second antigen binding portion comprising an anti-TIGIT antigen binding domain comprising:

- i. a second heavy chain variable domain comprising a vhCDR1, vhCDR2, and vhCDR3 from an anti-TIGIT antibody; and
- ii. a second light chain variable domain comprising a vlCDR1, vlCDR2, and vlCDR3 from an anti-TIGIT antibody;

wherein the anti-TIGIT antigen binding domain is selected from the group consisting of CPA.9.086 (vhCDR1 of SEQ ID NO:1635, vhCDR2 of SEQ ID NO:1636, and vhCDR3 of SEQ ID NO:1637; and vlCDR1 of SEQ ID NO:1640, vlCDR2 of SEQ ID NO:1641, and vlCDR3 of SEQ ID NO:1642), CHA.9.547.18 (vhCDR1 of SEQ ID NO:1665, vhCDR2 of SEQ ID NO:1666, and vhCDR3 of SEQ ID NO:1667; and vlCDR1 of SEQ ID NO:1669, vlCDR2 of SEQ ID NO:1670, and vlCDR3 of SEQ ID NO:1671), CPA.9.018 (vhCDR1 of SEQ ID NO:1673, vhCDR2 of SEQ ID NO:1674, and vhCDR3 of SEQ ID NO:1675; and vlCDR1 of SEQ ID NO:1678, vlCDR2 of SEQ ID NO:1679, and vlCDR3 of SEQ ID NO:1680), CPA.9.027 (vhCDR1 of SEQ ID NO:1683, vhCDR2 of SEQ ID NO:1684, and vhCDR3 of SEQ ID NO:1685; and vlCDR1 of SEQ ID NO:1688, vlCDR2 of SEQ ID NO:1689, and vlCDR3 of SEQ ID NO:1690), CPA.9.049 (vhCDR1 of SEQ ID NO:1693, vhCDR2 of SEQ

ID NO:1694, and vhCDR3 of SEQ ID NO:1695; and vlCDR1 of SEQ ID NO:1698, vlCDR2 of SEQ ID NO:1699, and vlCDR3 of SEQ ID NO:1700), CPA.9.057 (vhCDR1 of SEQ ID NO:1703, vhCDR2 of SEQ ID NO:1704, and vhCDR3 of SEQ ID NO:1705; and vlCDR1 of SEQ ID NO:1708, vlCDR2 of SEQ ID NO:1709, and vlCDR3 of SEQ ID NO:1710), CPA.9.059 (vhCDR1 of SEQ ID NO:1713, vhCDR2 of SEQ ID NO:1714, and vhCDR3 of SEQ ID NO:1715; and vlCDR1 of SEQ ID NO:1718, vlCDR2 of SEQ ID NO:1719, and vlCDR3 of SEQ ID NO:1720), CPA.9.083 (vhCDR1 of SEQ ID NO:1723, vhCDR2 of SEQ ID NO:1724, and vhCDR3 of SEQ ID NO:1725; and vlCDR1 of SEQ ID NO:1728, vlCDR2 of SEQ ID NO:1729, and vlCDR3 of SEQ ID NO:1730), CPA.9.089 (vhCDR1 of SEQ ID NO:1743, vhCDR2 of SEQ ID NO:1744, and vhCDR3 of SEQ ID NO:1745; and vlCDR1 of SEQ ID NO:1748, vlCDR2 of SEQ ID NO:1749, and vlCDR3 of SEQ ID NO:1750), CPA.9.093 (vhCDR1 of SEQ ID NO:1753, vhCDR2 of SEQ ID NO:1754, and vhCDR3 of SEQ ID NO:1755; and vlCDR1 of SEQ ID NO:1758, vlCDR2 of SEQ ID NO:1759, and vlCDR3 of SEQ ID NO:1760), CPA.9.101 (vhCDR1 of SEQ ID NO:1763, vhCDR2 of SEQ ID NO:1764, and vhCDR3 of SEQ ID NO:1765; and vlCDR1 of SEQ ID NO:1768, vlCDR2 of SEQ ID NO:1769, and vlCDR3 of SEQ ID NO:1770), CPA.9.103 (vhCDR1 of SEQ ID NO:1773, vhCDR2 of SEQ ID NO:1774, and vhCDR3 of SEQ ID NO:1775; and vlCDR1 of SEQ ID NO:1778, vlCDR2 of SEQ ID NO:1779, and vlCDR3 of SEQ ID NO:1780), CHA.9.536.1 (vhCDR1 of SEQ ID NO:1803, vhCDR2 of SEQ ID NO:1804, and vhCDR3 of SEQ ID NO:1805; and vlCDR1 of SEQ ID NO:1808, vlCDR2 of SEQ ID NO:1809, and vlCDR3 of SEQ ID NO:1810), CHA.9.536.3 (vhCDR1 of SEQ ID NO:1813, vhCDR2 of SEQ ID NO:1814, and vhCDR3 of SEQ ID NO:1815; and vlCDR1 of SEQ ID NO:1818, vlCDR2 of SEQ ID NO:1819, and vlCDR3 of SEQ ID NO:1820), CHA.9.536.4 (vhCDR1 of SEQ ID NO:1823, vhCDR2 of SEQ ID NO:1824, and vhCDR3 of SEQ ID NO:1825; and vlCDR1 of SEQ ID

NO:1828, vlCDR2 of SEQ ID NO:1829, and vlCDR3 of SEQ ID NO:1830), CHA.9.536.5 (vhCDR1 of SEQ ID NO:1833, vhCDR2 of SEQ ID NO:1834, and vhCDR3 of SEQ ID NO:1835; and vlCDR1 of SEQ ID NO:1838, vlCDR2 of SEQ ID NO:1839, and vlCDR3 of SEQ ID NO:1840), CHA.9.536.6 (vhCDR1 of SEQ ID NO:1843, vhCDR2 of SEQ ID NO:1844, and vhCDR3 of SEQ ID NO:1845; and vlCDR1 of SEQ ID NO:1848, vlCDR2 of SEQ ID NO:1849, and vlCDR3 of SEQ ID NO:1850), CHA.9.536.7 (vhCDR1 of SEQ ID NO:1853, vhCDR2 of SEQ ID NO:1854, and vhCDR3 of SEQ ID NO:1855; and vlCDR1 of SEQ ID NO:1858, vlCDR2 of SEQ ID NO:1859, and vlCDR3 of SEQ ID NO:1860), CHA.9.536.8 (vhCDR1 of SEQ ID NO:1863, vhCDR2 of SEQ ID NO:1864, and vhCDR3 of SEQ ID NO:1865; and vlCDR1 of SEQ ID NO:1868, vlCDR2 of SEQ ID NO:1869, and vlCDR3 of SEQ ID NO:1870), CHA.9.560.1 (vhCDR1 of SEQ ID NO:1873, vhCDR2 of SEQ ID NO:1874, and vhCDR3 of SEQ ID NO:1875; and vlCDR1 of SEQ ID NO:1878, vlCDR2 of SEQ ID NO:1879, and vlCDR3 of SEQ ID NO:1880), CHA.9.560.3 (vhCDR1 of SEQ ID NO:1883, vhCDR2 of SEQ ID NO:1884, and vhCDR3 of SEQ ID NO:1885; and vlCDR1 of SEQ ID NO:1888, vlCDR2 of SEQ ID NO:1889, and vlCDR3 of SEQ ID NO:1890), CHA.9.560.4 (vhCDR1 of SEQ ID NO:1893, vhCDR2 of SEQ ID NO:1894, and vhCDR3 of SEQ ID NO:1895; and vlCDR1 of SEQ ID NO:1898, vlCDR2 of SEQ ID NO:1899, and vlCDR3 of SEQ ID NO:1900), CHA.9.560.5 (vhCDR1 of SEQ ID NO:1903, vhCDR2 of SEQ ID NO:1904, and vhCDR3 of SEQ ID NO:1905; and vlCDR1 of SEQ ID NO:1908, vlCDR2 of SEQ ID NO:1909, and vlCDR3 of SEQ ID NO:1910), CHA.9.560.6 (vhCDR1 of SEQ ID NO:1913, vhCDR2 of SEQ ID NO:1914, and vhCDR3 of SEQ ID NO:1915; and vlCDR1 of SEQ ID NO:1918, vlCDR2 of SEQ ID NO:1919, and vlCDR3 of SEQ ID NO:1920), CHA.9.560.7 (vhCDR1 of SEQ ID NO:1923, vhCDR2 of SEQ ID NO:1924, and vhCDR3 of SEQ ID NO:1925; and vlCDR1 of SEQ ID NO:1928, vlCDR2 of SEQ ID NO:1929, and vlCDR3 of SEQ ID

NO:1930), CHA.9.560.8 (vhCDR1 of SEQ ID NO:1933, vhCDR2 of SEQ ID NO:1934, and vhCDR3 of SEQ ID NO:1935; and vlCDR1 of SEQ ID NO:1938, vlCDR2 of SEQ ID NO:1939, and vlCDR3 of SEQ ID NO:1940), CHA.9.546.1 (vhCDR1 of SEQ ID NO:1943, vhCDR2 of SEQ ID NO:1944, and vhCDR3 of SEQ ID NO:1945; and vlCDR1 of SEQ ID NO:1948, vlCDR2 of SEQ ID NO:1949, and vlCDR3 of SEQ ID NO:1950), CHA.9.547.1 (vhCDR1 of SEQ ID NO:1953, vhCDR2 of SEQ ID NO:1954, and vhCDR3 of SEQ ID NO:1955; and vlCDR1 of SEQ ID NO:1958, vlCDR2 of SEQ ID NO:1959, and vlCDR3 of SEQ ID NO:1960), CHA.9.547.2 (vhCDR1 of SEQ ID NO:1963, vhCDR2 of SEQ ID NO:1964, and vhCDR3 of SEQ ID NO:1965; and vlCDR1 of SEQ ID NO:1968, vlCDR2 of SEQ ID NO:1969, and vlCDR3 of SEQ ID NO:1970), CHA.9.547.3 (vhCDR1 of SEQ ID NO:1973, vhCDR2 of SEQ ID NO:1974, and vhCDR3 of SEQ ID NO:1975; and vlCDR1 of SEQ ID NO:1978, vlCDR2 of SEQ ID NO:1979, and vlCDR3 of SEQ ID NO:1980), CHA.9.547.4 (vhCDR1 of SEQ ID NO:1983, vhCDR2 of SEQ ID NO:1984, and vhCDR3 of SEQ ID NO:1985; and vlCDR1 of SEQ ID NO:1988, vlCDR2 of SEQ ID NO:1989, and vlCDR3 of SEQ ID NO:1990), CHA.9.547.6 (vhCDR1 of SEQ ID NO:1993, vhCDR2 of SEQ ID NO:1994, and vhCDR3 of SEQ ID NO:1995; and vlCDR1 of SEQ ID NO:1998, vlCDR2 of SEQ ID NO:1999, and vlCDR3 of SEQ ID NO:2000), CHA.9.547.7 (vhCDR1 of SEQ ID NO:2003, vhCDR2 of SEQ ID NO:2004, and vhCDR3 of SEQ ID NO:2005; and vlCDR1 of SEQ ID NO:2008, vlCDR2 of SEQ ID NO:2009, and vlCDR3 of SEQ ID NO:2010), CHA.9.547.8 (vhCDR1 of SEQ ID NO:2013, vhCDR2 of SEQ ID NO:2014, and vhCDR3 of SEQ ID NO:2015; and vlCDR1 of SEQ ID NO:2018, vlCDR2 of SEQ ID NO:2019, and vlCDR3 of SEQ ID NO:2020), CHA.9.547.9 (vhCDR1 of SEQ ID NO:2023, vhCDR2 of SEQ ID NO:2024, and vhCDR3 of SEQ ID NO:2025; and vlCDR1 of SEQ ID NO:2028, vlCDR2 of SEQ ID NO:2029, and vlCDR3 of SEQ ID NO:2030), CHA.9.547.13 (vhCDR1 of SEQ ID NO:1655, vhCDR2 of

SEQ ID NO:1656, and vhCDR3 of SEQ ID NO:1657; and vlCDR1 of  
SEQ ID NO:1660, vlCDR2 of SEQ ID NO:1661, and vlCDR3 of SEQ ID  
NO:1662), CHA.9.541.1 (vhCDR1 of SEQ ID NO:2033, vhCDR2 of SEQ  
ID NO:2034, and vhCDR3 of SEQ ID NO:2035; and vlCDR1 of SEQ ID  
NO:2038, vlCDR2 of SEQ ID NO:2039, and vlCDR3 of SEQ ID  
NO:2040), CHA.9.541.3 (vhCDR1 of SEQ ID NO:2043, vhCDR2 of SEQ  
ID NO:2044, and vhCDR3 of SEQ ID NO:2045; and vlCDR1 of SEQ ID  
NO:2048, vlCDR2 of SEQ ID NO:2049, and vlCDR3 of SEQ ID  
NO:2050), CHA.9.541.4 (vhCDR1 of SEQ ID NO:2053, vhCDR2 of SEQ  
ID NO:2054, and vhCDR3 of SEQ ID NO:2055; and vlCDR1 of SEQ ID  
NO:2058, vlCDR2 of SEQ ID NO:2059, and vlCDR3 of SEQ ID  
NO:2060), CHA.9.541.5 (vhCDR1 of SEQ ID NO:2063, vhCDR2 of SEQ  
ID NO:2064, and vhCDR3 of SEQ ID NO:2065; and vlCDR1 of SEQ ID  
NO:2068, vlCDR2 of SEQ ID NO:2069, and vlCDR3 of SEQ ID  
NO:2070), CHA.9.541.6 (vhCDR1 of SEQ ID NO:2073, vhCDR2 of SEQ  
ID NO:2074, and vhCDR3 of SEQ ID NO:2075; and vlCDR1 of SEQ ID  
NO:2078, vlCDR2 of SEQ ID NO:2079, and vlCDR3 of SEQ ID  
NO:2080), CHA.9.541.7 (vhCDR1 of SEQ ID NO:2083, vhCDR2 of SEQ  
ID NO:2084, and vhCDR3 of SEQ ID NO:2085; and vlCDR1 of SEQ ID  
NO:2088, vlCDR2 of SEQ ID NO:2089, and vlCDR3 of SEQ ID  
NO:2090), and CHA.9.541.8 (vhCDR1 of SEQ ID NO:2093, vhCDR2 of  
SEQ ID NO:2094, and vhCDR3 of SEQ ID NO:2095; and vlCDR1 of  
SEQ ID NO:2098, vlCDR2 of SEQ ID NO:2099, and vlCDR3 of SEQ ID  
NO:2100)~~CPA.9.018, CPA.9.027, CPA.9.049, CPA.9.057, CPA.9.059,~~  
~~CPA.9.083, CPA.9.086, CPA.9.089, CPA.9.093, CPA.9.101, CPA.9.103,~~  
~~CHA.9.536.1, CHA.9.536.3, CHA.9.536.4, CHA.9.536.5, CHA.9.536.6,~~  
~~CHA.9.536.7, CHA.9.536.8, CHA.9.560.1, CHA.9.560.3, CHA.9.560.4,~~  
~~CHA.9.560.5, CHA.9.560.6, CHA.9.560.7, CHA.9.560.8, CHA.9.546.1,~~  
~~CHA.9.547.1, CHA.9.547.2, CHA.9.547.3, CHA.9.547.4, CHA.9.547.6,~~  
~~CHA.9.547.7, CHA.9.547.8, CHA.9.547.9, CHA.9.547.13, CHA.9.541.1,~~

~~CHA.9.541.3, CHA.9.541.4, CHA.9.541.5, CHA.9.541.6, CHA.9.541.7,  
CHA.9.541.8, and CHA.9.547.18.~~

39. An anti-PVRIG antibody comprising:

i) a heavy chain or heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from the following sequence:

QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQGLEWMGYIYPYIGGSGYAQKFQGRV  
TMTRDTSTSTVYMELSSLRSED TAVYYCAREDKTARNAMDYWGQGLTVTVSS (SEQ ID  
NO:3179) ,

and

ii) a light chain or light chain variable domain comprising the vlCDR1, vlCDR2, vlCDR3 from the following sequence:

DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPKLLIYEATNLAEGVPSRFSGSGSG  
TDFTLTISSLQPEDFATYYCQHFVGTPTFTFGQGTKLEIK (SEQ ID NO:3180) .

40. An anti-TIGIT antibody comprising:

i) a heavy chain or heavy chain variable domain comprising the vhCDR1, vhCDR2, and vhCDR3 from the following sequence:

EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYIMSWVRQAPGKGLEWVATISGGSKGQYYADSVKGRF  
TISRDN SKNTLYLQMNSLRAEDTAVYYCAKWLLSYIAMDYWGQGLTVTVSS (SEQ ID  
NO:1664) ,

and

ii) a light chain or light chain variable domain comprising the vlCDR1, vlCDR2, and vlCDR3 from the following sequence:

DIQMTQSPSSLSASVGDRITITCRASQSMALWSWYQQKPGKAPKLLIYKASKSHTGVPSRFSGSGSG  
TDFTLTISSLQPEDFATYYCQQGQSYPTFTFGQGTKLEIK (SEQ ID NO:1668) .

41. The anti-PVRIG antibody of claim ~~38-39~~ comprising:

a) a heavy chain comprising CHA.7.518.4 ~~VH~~ heavy chain

(QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNINWVRQAPGQGLEW  
MGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYMELSSLRSED TAVYYC  
AREDKTARNAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSESTAAL  
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL  
GTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAQGPSVFLFPPK  
PKDTLMISRTPEVTCVVDVVKQEDPEVQFNWYVDGVEVHNAKTKPREE

QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR  
EPQVYTLPPSSEQMTKNQV~~KL~~TCLVKGFYPSDIAVEWESNGQPENNYKT  
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL  
SPGQVQLVQSGAEVKKPGASVKVSCKASGYTF~~TD~~YNINWVRQAPGQGLE  
WMGYIYPYIGGSGYAQKFQGRVTMTRDTSTSTVYME~~LS~~SLRSEDTAVYY  
CAREDKTARNAMDYWGQGT~~L~~TVSSASTKGPSVFPLAPCSRSTSESTA  
LGCLVKDYFPEPVT~~SV~~WNSGALTSGVHTFPAVLQSSGLYSLSSV~~TV~~PPSS  
LGTKTYTCNV~~DH~~KPSNTKVDKRVESKYGPPCP~~PA~~PEFLGGPSVFLFPPK  
PKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQ  
FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPRE  
PQVYTLPP~~CQDEL~~TKNQVSL~~W~~C~~L~~VKGFYPSDIAVEWESNGQPENNYKTT  
PPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS  
PGK; SEQ ID NO: 31753357); and

- b) a light chain comprising CHA.7.518.4 ~~VL~~-light chain  
(DIQMTQSPSSLSASVGDRVTITCRVSENIYDVLAWYQQKPGKAPKLLIYE  
ATNLAEGVPSRFGSGSGTDFTLTIS~~SL~~LQPEDFATYYCQHF~~WG~~TPYTFGQG  
TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD  
NALQSGNSQESVTEQDSKDYSLSS~~TL~~TLTKADYEKHKVYACEVTHQG  
LSSPVTKSFNRGEC ; SEQ ID NO: 3362).
42. A composition comprising an anti-PVRIG antibody according to claim 38-39 or claim 4041.
  43. A nucleic acid composition comprising:
    - i) a first nucleic acid encoding a heavy chain or heavy chain variable domain according to claim 38-39 or claim 4041; and
    - ii) a second nucleic acid encoding a light chain or light chain variable domain according to claim 38-39 or claim 4041.
  44. A composition comprising an anti-TIGIT antibody according to claim 3940.
  45. A nucleic acid composition comprising:
    - i) a first nucleic acid encoding a heavy chain or heavy chain variable domain according to claim 3840; and

- ii) a second nucleic acid encoding a light chain or light chain variable domain according to claim ~~38~~40.
46. An expression vector composition comprising:
- i) a first expression vector comprising the first nucleic acid of claim ~~41~~43; and
  - ii) a second expression vector comprising the second nucleic acid of claim ~~41~~43.
47. An expression vector comprising:
- i) the first nucleic acid of claim ~~41~~43; and
  - ii) the second nucleic acid of claim ~~41~~43.
48. An expression vector composition comprising:
- i) a first expression vector comprising the first nucleic acid of claim ~~43~~45; and
  - ii) a second expression vector comprising the second nucleic acid of claim ~~43~~45.
49. An expression vector comprising:
- i) the first nucleic acid of claim ~~43~~45; and
  - ii) the second nucleic acid of claim ~~43~~45.
50. A host cell comprising the expression vector or vector composition of anyone of claims ~~44-46~~ to ~~47~~49.
51. A method of making an anti-PVRIG or anti-TIGIT antibody comprising:
- i) culturing the host cell of claim ~~48-50~~ under conditions wherein the antibody is expressed; and
  - ii) recovering the antibody.
52. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating T cells of ~~a~~the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated.
53. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of ~~a~~the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated.

54. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating NK cells of a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the NK cells of the patient are to be activated.
55. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are to be activated.
56. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating Th1 cells of a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient are to be activated.
57. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in a the cancer patient, wherein said antibody is to be administered to the patient.
58. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in a the cancer patient, wherein said antibody is to be administered to the patient.
59. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating cancer in a patient, wherein said antibody is to be administered to the patient.
60. The use of claim ~~58~~59, wherein the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin

cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

61. The use of claim [5859](#), wherein the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).
62. Use of an anti-PVRIG/anti-TIGIT bispecific antibody according to any one of claims 1 to 20 in the manufacture of a medicament for use in combination therapy for treating cancer in a patient.
63. Use of an anti-PVRIG antibody of claim [38-39](#) and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient.
64. The use according to claim 63, wherein the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab, cemiplimab and nivolumab.
65. Use of an anti-TIGIT antibody of claim [39-40](#) and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient.
66. The use according to claim 65, wherein the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab, cemiplimab and nivolumab.
67. Use of an anti-TIGIT antibody of claim [39-40](#) and an anti-PVRIG antibody of claim 38 in the manufacture of a medicament for combination therapy to treat cancer in a patient.
68. Use of an anti-TIGIT antibody of claim [3940](#), an anti-PVRIG antibody, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient.

69. Use of an anti-TIGIT, an anti-PVRIG antibody of claim ~~38~~39, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient.
70. Use of an anti-TIGIT of claim ~~39~~40, an anti-PVRIG antibody of claim ~~38~~39, and either an anti-PD-1 antibody or an anti-PD-L1 antibody in the manufacture of a medicament for combination therapy to treat cancer in a patient.
71. The use according to any one of claims 63 to 65 and 68 to 70, wherein the anti-PD-1 antibody is an antibody selected from the group consisting of pembrolizumab, cemiplimab and nivolumab.
72. The use according to any one of claims 63 to 66 and 68 to 70, wherein the anti-PD-L1 antibody is an antibody selected from the group consisting of atezolizumab, avelumab, and durvalumab.
73. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating T cells of ~~the~~a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the T cells of the patient are to be activated.
74. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating cytotoxic T cells (CTLs) of ~~a the~~a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the CTLs of the patient are to be activated.
75. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating  $\gamma\delta$  T cells of ~~a the~~a the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the  $\gamma\delta$  T cells of the patient are to be activated.
76. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by activating Th1

cells of ~~a~~the cancer patient, wherein said antibody is to be administered to the patient, wherein a subset of the Th1 cells of the patient are to be activated.

77. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by decreasing or eliminating cell number and/or activity of at least one of regulatory T cells (Tregs) in ~~a~~the cancer patient, wherein said antibody is to be administered to the patient.

78. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating a cancer patient by increasing interferon- $\gamma$  production and/or pro-inflammatory cytokine secretion in ~~a~~the cancer patient, wherein said antibody is to be administered to the patient.

79. Use of the anti-PVRIG or anti-TIGIT antibody of ~~any one of claims 38 to 40~~claim 39 or 40 in the manufacture of a medicament for treating cancer in a patient, wherein said antibody is to be administered to the patient.

80. The use of claim 79, wherein the cancer is selected from the group consisting of prostate cancer, liver cancer (HCC), colorectal cancer, ovarian cancer, endometrial cancer, breast cancer, triple negative breast cancer, pancreatic cancer, stomach (gastric) cancer, cervical cancer, head and neck cancer, thyroid cancer, testis cancer, urothelial cancer, lung cancer (small cell lung, non-small cell lung), melanoma, non melanoma skin cancer (squamous and basal cell carcinoma), glioma, renal cancer (RCC), lymphoma (NHL or HL), Acute myeloid leukemia (AML), T cell Acute Lymphoblastic Leukemia (T-ALL), Diffuse Large B cell lymphoma, testicular germ cell tumors, mesothelioma, esophageal cancer, Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

81. The use of claim 79, wherein the cancer is selected from the group consisting of triple negative breast cancer, stomach (gastric) cancer, lung cancer (small cell lung, non-small cell lung), Merkel Cells cancer, MSI-high cancer, KRAS mutant tumors, adult T-cell leukemia/lymphoma, myeloma, and Myelodysplastic syndromes (MDS).

82. Use of an anti-PVRIG/anti-TIGIT bispecific antibody in the manufacture of a medicament for activating T cells and/or NK cells for the treatment of cancer, wherein

said bispecific antibody monovalently binds a human PVRIG and monovalently binds TIGIT.